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Chapter 1 
 





Neuroendocrine tumours (NET) are a heterogeneous group of rare tumours, arising from 
cells of the neuroendocrine or endocrine system. The cells that belong to this 
(neuro)endocrine system are dispersed throughout the entire body and capable of 
secreting several (neuro)endocrine factors; hormones, bioactive amines and 
polypeptides.  
The neuroendocrine cells can be divided into cell types that form localised glands 
(adenohypophysis, the parathyroids, the paraganglia and the adrenal medulla) and cells 
that are disseminated throughout the body in other organs: the diffuse neuroendocrine 
system.1 Tumours from the adenohypophysis are called adenomas with an indication of 
the main cell type (for instance corticotroph adenoma), tumours from the parathyroid are 
mostly adenomas, carcinomas from both are rare. Endocrine tumours originating from 
chromaffin cells of the adrenal medulla are called phaeochromocytoma. Tumours of the 
sympathetic and parasympathetic paraganglia are classified as paragangliomas.2   
The term carcinoid was introduced by Oberndorfer in 1907, to describe a carcinoma-like 
tumour.3 Decades later in 1963 Williams and Sandler classified the carcinoid tumours 
into foregut, midgut and hindgut tumours according to their embryological origin.4 Foregut 
endocrine cells give rise to tumours in the respiratory tract, the stomach, the first part of 
the duodenum and the pancreas. Midgut carcinoid tumours are derived from endocrine 
cells in the second part of the duodenum, jejunum, ileum and proximal part of the colon. 
Hindgut carcinoid tumours originate from cell the remaining part of the colon, and 
rectum.  
Recently, in 2000, a new a universal classification from the World Health Organisation 
(WHO) became available for NETs of the gastrointestinal tract. All gastroenteropancreatic 
(GEP) NETs are now categorised based on histological features; 1) well differentiated 
(neuro)endocrine tumours of probable benign behaviour, 2) well differentiated 
(neuro)endocrine tumours of uncertain behaviour, 3) well differentiated (neuro)endocrine 
carcinomas and  4) poorly differentiated (neuro)endocrine carcinomas.5  
The tumour that was originally described by Oberndorfer, the midgut carcinoid tumour is, 
according to the WHO classification a well-differentiated neuroendocrine carcinoma of 
the small bowel or proximal colon.  
In this thesis the term midgut carcinoid tumour is used to describe this well differentiated 
NET of the gastrointestinal tract. 
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Midgut carcinoid tumours 
As explained above midgut carcinoid tumours are derived from the enterochromaffin cells 
in the duodenum, jejunum, ileum and proximal part of the colon.  
The incidence rate of midgut carcinoid tumours is about 0.75 per 100.000 per 
population/year in the United States, whereas the Dutch incidence rate is about 1.95 per 
100,000 per population/year for all carcinoid tumours.6,7    
The enterochromaffin cells are capable of synthesising and secreting serotonin, a 
biogenic amine. Serotonin is the most important factor secreted by midgut carcinoid 
tumours and is synthesised from the amino acid tryptophan through 5-hydroxytryptophan 
(5-HTP) (Figure 1).8  
 
Figure 1. Cellular synthesis of serotonin through tryptophan 
 
 
TPH: tryptophan hydroxylase, AADC: aromatic-L-amino acid decarboxylase, IDO: indolamine dioxygenase, 
TDO: tryptophan dioxygenase. 
 
Next to serotonin, midgut carcinoid tumours are capable of secreting other biogenic 
amines such as catecholamines and several other factors such as kallikrein, tachykinins, 
and chromogranin A (CgA).9-11 When large amounts of serotonin and others factors enter 
the systemic circulation, usually in the presence of liver metastases, the carcinoid 
syndrome can develop. 
The carcinoid syndrome consists of several symptoms with flushes, diarrhoea and 
carcinoid heart disease being the most important ones. Identifying the overproduction of 
serotonin and its major metabolite, 5-hydroxyindolacetic acid (5-HIAA) in the urine assists 
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Localising the tumour and its metastases is accomplished by ultrasonography, computed 
tomography (CT), magnetic resonance imaging (MRI), and with nuclear scans. 111In-
octreotide scintigraphy (SRS) visualises somatostatin receptors on the cell surface.14 
Metaiodobenzylguanidine (MIBG) is an analogue of norepinephrine taken up by 
neuroendocrine cells. MIBG can be labelled with 123iodine(I) or 131I for visualisation.15 A 
recent publication shows that 6-[18F]-fluoro-L-dihydroxyphenylalanine (18F-DOPA) positron 
emission tomography (PET) is the best nuclear scan technique to detect carcinoid tumour 
lesions by visualising cellular metabolism.16  
Next to imaging studies to identify tumour localisation, echocardiography is advised for 
the detection of carcinoid heart disease.17,18  
The treatment of patients with extensive metastatic disease is, if surgery is no longer 
possible, palliative and aimed at reducing tumour size, reducing secreted factors by the 
tumour and improving the quality of life (QoL).19-22 Somatostatin analogues and interferon 
(IFN) alpha are both registered agents for this indication and capable to reduce 
symptoms and lower the urinary 5-HIAA concentrations. Both somatostatin analogues 
and IFN-alpha have limited effect on tumour growth.23 Other treatment modalities include 
radionuclide therapy with radiolabelled somatostatin analogues, radiofrequent ablation 
and (chemo-) embolisation of liver metastases.24-27 
Despite the fact that most patients cannot be cured, survival is relatively long. The 5 year 
survival rate of patients with metastatic carcinoid tumours is about 60% but survival 




Phaeochromocytomas originate from the chromaffin cells in the medulla or paraganglia 
and secrete biogenic amines: epinephrine, norepinephrine and dopamine. The incidence 
is about 2.06 per 1,000,000 per population/year.28 They can occur isolated and in 
patients with familial syndromes such as multiple endocrine neoplasia (MEN) type 2a and 
type 2b, von Hippel Lindau disease and in families with succinate dehydrogenase (SDH) 
mutations. Mutations in one of these genes responsible for the familial syndromes have 
been found in up to 24% of apparent sporadic cases.29,30 Symptoms occur when 
catecholamines are released into the circulation leading to hypertension, palpitations and 
sweating. Phaeochromocytomas are benign in approximately 90% of the cases, however 
when left untreated they are fatal because of cardiovascular complications due to 
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massive release of catecholamines. The diagnosis of a phaeochromocytoma is made by 
the identification of the metabolites of epinephrine, norepinephrine or dopamine in 
plasma or in urine.31 Once the diagnosis is made, localisation is done by CT or MRI and 
functional scanning with the use of 123I-MIBG scintigraphy. Therapy of a benign 
phaeochromocytoma consists of resection of the tumour preceded by a preoperatively 
blockade of the alpha and beta-receptors.32 After resection lifelong follow-up is needed 







The aim of this thesis is to evaluate the course and follow-up of patients with NETs 
focussing on the midgut carcinoid tumours and phaeochromocytomas.  
In chapter 2 we present an overview of the current literature concerning symptoms of the 
carcinoid syndrome, with the emphasis on cardiovascular symptoms. 
Known unfavourable factors for survival are age, high urinary 5-HIAA concentrations at 
first visit, high plasma CgA levels, the presence of liver or lymph node metastases, the 
presence of carcinoid heart disease, the tumour size, and the histological grade of 
differentiation. In only one study prognostic factors during follow-up have been 
identified.33 Turner and colleagues observed that plasma neurokinin A (NKA) levels 
during follow-up were related to outcome. For other factors, data were available from only 
a small number of patients. In chapter 3.1 we focus on survival and prognostic factors, 
using a database of midgut carcinoid patients, selecting 76 patients referred between 
1992 and 2003. It would be helpful to have a non-invasive cheap marker that indicates 
prognosis during follow-up in addition to radiological tumour measurements because 
these are difficult and radiological progression in these patients is generally slow. 
Especially since numerous targeted drugs are currently under investigation, other 
prognostic factors may be useful to guide decisions in treatment. Therefore the aim of 
this study was to determine predictive factors of survival in patients with metastatic 
midgut carcinoid tumours, with the emphasis on the urinary 5-HIAA concentration. We 
performed analyses to identify prognostic factors at referral including age, gender, the 
urinary 5-HIAA concentrations, the presence of liver metastases, the resection of the 
primary tumour at referral, and liver enzymes at referral. To study the prognostic value of 
the urinary 5-HIAA concentrations during follow-up, we also performed a multivariate 
analysis with the urinary 5-HIAA level as a time-dependent covariable. 
Chapter 3.2 is our response to a study of Møller and colleagues in which we describe the 
course of the urinary 5-HIAA concentration during follow-up of patients with the carcinoid 
syndrome.34 
In chapter 4 we study the effect of genetic variations in the metabolism of serotonin on 
symptoms and survival. Serotonin is taken up by the serotonin transporter (SERT, or 5-
HTT) and metabolised to 5-HIAA by monoamine oxidase A (MAO-A). A functional 
polymorphism in the promoter region of the SERT (5-HTTLPR), with a short (S) and a long 
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(L) allele exists. A functional polymorphic region (upstream variable number of tandem 
repeats (uVNTR)) is also known for the MAO-A gene. Given the prominent role of 
serotonin, we hypothesized that these polymorphisms affect the presence of symptoms 
of the carcinoid syndrome and survival. A total of 105 patients with metastatic midgut 
carcinoid tumours were genotyped for 5-HTTLPR and uVNTR-MAO-A. Differences between 
genotypic groups were tested and correlated with the presence of flushes and diarrhoea. 
Next we studied the effect of the different genotypes on death within 5 to 10 years after 
follow-up adjusted for the urinary 5-HIAA concentration at referral, age at referral and the 
presence of liver metastases. 
The new targeted drugs for NETs are mainly directed at angiogenesis, as these tumours 
are highly vascularised and vascular endothelial growth factors (VEGF) and its receptors 
are highly present. In chapter 5 we describe the results of a feasibility study with IFN-
alpha (2.5 million U/day subcutaneously), intravenous 5-fluorouracil (5-FU) 750 mg/m2 
and oral leucovorin 180 mg/day as a 2 weekly cycle in patients with metastatic NETs. 
Because of the suggested synergistic and antiangiogenic effects between 5-FU and IFN-
alpha, we determined serial serum VEGF levels to investigate whether serum VEGF levels 
decrease after treatment. 
Next to relieving symptoms and prolonging life, treatment of patients with midgut 
carcinoid tumours is aimed at but also at improving the QoL. Sexual function is a part of 
the QoL, but rarely studied. In chapter 6 we focus on this issue. There are several 
potential underlying mechanisms that could make patients with midgut carcinoid tumours 
prone to sexual dysfunction. In the brain serotonin is involved in sexual behaviour. It has 
been suggested that patients with midgut carcinoid tumours have a depleted serotonin 
pool in the brain. Furthermore serotonin and other factors have vasoactive properties 
that could lead to erectile dysfunction in male patients Next to these specific causes, 
patients can experience pain, fatigue and use medication that may affect the ability and 
desire to have sexual activity. A total of 43 patients with metastatic midgut carcinoid 
tumours filled in a validated questionnaire on sexual function. The outcome on different 
subscales was compared to a population based Dutch reference sample. To study 
possible underlying mechanisms and create hypotheses for future interventions, we also 
investigated whether sexual dysfunction was correlated with tumour activity and/or 
changes in gonadal hormones. 
In chapter 7 we study the role of 123I-MIBG scintigraphy in the work-up of patients with 
phaeochromocytomas. Recommendations on the use of 123I-MIBG scintigraphy in 
Chapter 1 
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localising phaeochromocytomas vary. We determined the accuracy of the 123I-MIBG 
scintigraphy by evaluating the 123I-MIBG scintigraphy of 30 patients treated in our 
hospital. We also performed a meta-analysis of previous studies including more than 5 
patients with 123I-MIBG scans. 
Finally, in chapter 8 our observations are summarised and future perspectives are 
addressed. 
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The carcinoid syndrome, associated with carcinoid tumours of the midgut, consists of 
symptoms such as diarrhoea, flushing, wheezing and cardiovascular symptoms. This 
review focuses on these symptoms and discusses therapeutic options. The symptoms are 
caused by the secretion of biogenic amines, polypeptides and other factors of which 
serotonin is the most prominent. However, diarrhoea is also due to factors such as 
malabsorption. Besides antitumour therapy, more specific interventions such as 
serotonin receptor blockers can be useful. The carcinoid heart disease involves the 
tricuspid and pulmonary valve. In the pathogenesis, serotonin plays a central role. The 
therapeutic approach is mostly symptomatic. Other cardiovascular complications include 
bowel ischemia and hypertension. Pellagra and psychiatric symptoms are due to a 
depletion of tryptophan, which is consumed by the carcinoid tumour for serotonin 
synthesis. Finally, the follow-up and clinical practice of patients with carcinoid tumours 
are discussed. 





Carcinoid tumours are rare slowly growing neuroendocrine tumours, with an incidence of 
2/100,000 population per year.1,2 According to the classification of Williams and Sandler, 
they are divided into tumours of the fore-, mid- and hindgut.3 Tumours of the midgut (the 
classic carcinoid tumours) originate in the enterochromaffin cells of the gut and have the 
ability to produce various factors.  
The carcinoid syndrome, described by Thorson and colleagues in 1954, is associated with 
carcinoid tumours of the midgut.4 This syndrome consists of a constellation of symptoms 
due to the secretion of large amounts of biogenic amines (serotonin, catecholamines and 
histamine), polypeptides and other factors, of which serotonin is the most prominent 
factor. Carcinoid tumours of the foregut produce less serotonin compared to midgut 
tumours, whereas tumours of the hindgut are seldom biochemical active.5-7 Therefore, 
the carcinoid syndrome is rarely associated with carcinoid tumours of the fore- and 
hindgut but typically associated with the carcinoid tumours of the midgut, usually in the 
presence of liver metastases. Normally serotonin, produced by the enterochromaffin cell 
or carcinoid tumour cell is transported to the liver through the portal vein and 
metabolised to 5-hydroxyindoleacetic acid (5-HIAA) by the liver cell (Figure 1).8 However, 
when serotonin enters the systemic circulation, as is the case in patients with liver 
metastases, but also in female patients with metastases in the ovaries, the typical 
symptoms of the carcinoid syndrome, such as diarrhoea, flushing, and carcinoid heart 
disease, can occur.  
The breakdown product of serotonin, 5-HIAA is secreted into the urine. The urinary 5-HIAA 
concentration is considered to be a reflection of tumour burden and therefore widely 
used as a marker for follow-up. Besides symptoms of the carcinoid syndrome, symptoms 
due to the tumour itself or the metastases can occur. Symptoms and complications of the 
carcinoid syndrome are becoming more relevant since survival seems to be improving. 
Five-year survival rates are ranging from 21 to 50% for carcinoid tumours of the small 
bowel with distant metastases. After the introduction of the somatostatin analogues, 
survival seemed to improve.1,2,9  
We will present an overview of symptoms of the carcinoid syndrome, focusing on the 







Figure 1. Synthesis of serotonin from tryptophan and enzymatic steps and major route of 




Diarrhoea occurs in about 80% of patients.10,11 Several underlying mechanisms have 
been identified, although data on the relative contribution are lacking. Malabsorption of 
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malabsorption of fat and bacterial overgrowth can all contribute to diarrhoea. Serotonin is 
the most important factor secreted by the tumour and causing incapacitating diarrhoea. 
Under normal circumstances, serotonin stimulates motility and secretion of the bowel 
through serotonin receptors.12 Other secreted factors such as histamine, kallikrein, 
prostaglandin, substance P and motilin might also play a role in the pathogenesis of 
diarrhoea.13,14 Van der Ohe and colleagues studied 16 patients with carcinoid tumours 
and 16 healthy controls and compared small bowel and colonic transit time.14 Transit 
time in the small bowel and colon was increased in the carcinoid patients.  
Diarrhoea can be a major burden on normal social life of patients. Therapy is aimed at 
lowering the secretion of serotonin and other factors by reducing tumour load by surgical 
intervention or biotherapy. Aggressive surgical treatment of the primary tumour, lymph 
node metastases and even liver metastases can ameliorate symptoms and improve 
survival.15,16 In inoperable patients, biotherapy with somatostatin analogues and 
interferon (IFN)-alpha are the treatment of choice.17,18 Blockade of serotonin receptors 
can also ameliorate diarrhoea.19,20 Chemotherapy is rarely indicated. 
Other medical interventions are aimed at reducing the colonic bile acids (bile acid 
sequestrants), improving fat absorption (pancreatic enzyme suppletion) and inhibiting 
peristalsis and decreasing transition time (loperamide). 
 
Flushing 
The prevalence of flushing is reported to be about 80%.10,11 Flushing has been linked to 
several factors; tachykinins, serotonin, catecholamines, and histamine.21-23 The exact 
pathogenesis remains unclear. Flushing usually is most prominent in the malar area of 
the face, the forehead and the V area of the neck. Certain food and alcohol can provoke 
it.24 Therapy consists of lowering the secretion of the various factors by surgical reduction 
of tumour load, IFN-alpha and/or somatostatin analogues. Some case reports describe 
the beneficial effect of blocking the histamine 1 and 2 receptor.25,26 
 
Wheezing 
Although wheezing is often mentioned as a hallmark of the carcinoid syndrome, it is only 
present in about 10% of the patients.11 The underlying mechanism is not clear. It often 
accompanies flushing. It should not be mistaken for asthma since administration of β2 





Carcinoid heart disease and cardiovascular complications 
Carcinoid heart disease develops in about 40% of patients.27,28 It is characterised by so-
called 'carcinoid plaques' on the right side with involvement of the tricuspid valve, 
pulmonary valve and endocardium. The most common manifestations are insufficiency of 
the tricuspid valve and to a lesser extent stenosis and pulmonary valve stenosis and 
insufficiency, resulting in right-sided heart failure.29 The underlying mechanism is 
considered to be the stimulation of transforming growth factors (TGFβ) by serotonin 
resulting in an increased collagen synthesis that in turn leads to carcinoid plaques.30-32 
Several studies show that patients with carcinoid heart disease have higher urinary 5-
HIAA excretions, compared to patients without carcinoid heart disease, supporting the 
theory that serotonin plays a major role in the carcinoid heart disease 
development.27,29,33,34 Although involvement of the left side of the heart is uncommon, 
because the pulmonary endothelium, like the liver, can metabolise serotonin to 5-HIAA, it 
does exist.35 Prognosis for patients with carcinoid heart disease is worse compared to 
those without carcinoid heart disease.29,36 Screening for carcinoid heart disease by 
performing a transthoracic echocardiography is recommended especially for patients with 
a urinary 5-HIAA excretion above 100 mg/24 hours.33 Therapy of carcinoid heart disease 
is symptomatic with diuretics. It is not clear whether somatostatin analogues inhibit or 
postpone the development of carcinoid heart disease.34,37 Surgical valve replacement 
leads to a decrease of symptoms but has a high perioperative mortality.35,38 
 
Other cardiovascular manifestations 
Although overproduction of serotonin is the hallmark of the carcinoid syndrome and 
carcinoid heart disease, other biogenic amines are also important. Catecholamines are 
produced and secreted in about 40% of patients.39,40 Heart rate variability, a sign of 
autonomic dysfunction, is impaired in an early stage of carcinoid heart disease and 
related to an increased urinary secretion of catecholamines and its metabolites.41-43 
Catecholamines can also lead to hypertension; however, data on the prevalence of 
hypertension are sparse. 
Elastic vascular sclerosis is a condition of the mesenteric blood vessel, consisting of a 
proliferation of the adventitial and intimal elastic fibers. The exact mechanism has to be 
elucidated, but it has been linked to serotonin, histamine and bradykinin.44 It can lead to 
ischemic intestinal changes in about 33% of the patients.44,45 These ischemic intestinal 
changes however can also result from entrapment of vessels in the fibrotic changes of 
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the mesentery.46 Another cardiovascular manifestation that has been described in some 
case reports is peripheral vasospasm.47 
 
Fibrotic complications 
Although not completely elucidated, serotonin is also held responsible for the fibrotic 
changes elsewhere throughout the body besides the heart. Extensive fibrotic changes 
may occur in the mesentery leading to obstruction and abdominal pain.46 Several patients 
with hydronephrosis due to retroperitoneal fibrosis have been reported.48,49 
 
Pellagra 
Pellagra is characterised by the triad dermatitis, diarrhoea and dementia. It is a result of 
a deficiency of niacin. Under normal circumstances, niacin can be obtained directly from 
the diet or it can be synthesised from tryptophan.50 Carcinoid tumours can consume 
about 60% of the body tryptophan as it is a precursor of serotonin. This leads to an 
impaired endogen niacin production. The prevalence of pellagra in patients with carcinoid 
tumours is about 5%.10 Treatment consists of the administration of niacin. 
 
Neuropsychological symptoms 
A depletion of body tryptophan can also result in an intracerebral deficiency of serotonin. 
The brain has its own ability to synthesise serotonin from tryptophan, since serotonin, in 
contrast to tryptophan, is not able to cross the blood-brain barrier. Intracerebral produced 
serotonin is involved in the regulation of sleep, sexuality, mood and eating. 
Neuropsychological investigation in patients with carcinoid syndrome has indicated that 
patients have an impaired sustained visual attention and an impulse control disorder.51,52 
Treating depression in patients with carcinoid syndrome can be a challenge for the 
treating physician, since the commonly used selective serotonin reuptake inhibitors might 
interfere with peripheral serotonin metabolism and therefore worsen symptoms of the 
carcinoid syndrome. 
 
Clinical practice and follow-up of patients with carcinoid syndrome 
The above-mentioned signs and symptoms are, like one would expect, variable in 
expression. It seems difficult to predict which symptoms will develop in an individual 
patient. However, despite the slow-growing nature of this malignancy and the relatively 




quality of life can be affected.53 It is not clear whether somatostatin analogues or IFN-
alpha improve survival, although increasing evidence for this hypothesis exists.2,9 Data 
about the optimal initial work-up and follow-up of a patient are lacking. After the 
diagnosis has been made, further diagnostics usually compromise an 111In-octreotide 
scintigraphy (somatostatin receptor scintigraphy: SRS) for the localisation of metastases 
and primary tumour. A computed tomography (CT) scan of the abdomen is often 
performed to evaluate liver metastases. Both diagnostics are helpful in the consideration 
of surgical interventions. A promising new technique is visualisation of the tumour and its 
metastases by 6-[18F]-fluoro-L-dihydroxyphenylalanine (18F-DOPA) positron emission 
tomography (PET). Biochemical evaluation includes chromogranin A and urinary excretion 
of 5-HIAA, markers for the effect of therapy and tumour progression.54 By regular 
measurement of these markers, e.g. every 3 months, one can evaluate the rate of 
progression of the tumour in individuals. Serotonin in platelets is the most sensitive 
indole marker in the primary biochemical diagnosis but not useful in follow-up.55 It is not 
clear whether measuring tryptophan every 3 months can predict symptoms of pellagra. 
Questions remain about performing SRS or CT scans regularly. It does not seem 
necessary for predicting symptoms of the carcinoid syndrome since an increment in the 
urinary excretion of 5-HIAA often seems to precede these symptoms. Evaluating carcinoid 
heart disease is recommended initially and for patients who are at risk, i.e. patients with 
an urinary 5-HIAA excretion above 100 mg/24 hours.33 Regular evaluation is important 
since one can anticipate right-sided heart failure and perhaps identify patients who will 
benefit from surgical valve replacement.35,38 It seems justified to perform other 
diagnostics only when an individual patient complains of certain mentioned symptoms, 





The carcinoid syndrome consists of a spectrum of symptoms. Treatment of these 
symptoms should not only consist of antitumour therapy but should also be based on the 
underlying pathogenesis, i.e. blocking a specific receptor. The optimal follow-up of this 
group of patients is not yet totally clear. Large databases will likely give more insight into 
this subject in the near future. 
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Survival of patients with metastatic midgut carcinoid tumours varies. We investigated 
which factors predict survival at referral and during follow-up, with the emphasis on 
urinary 5-hydroxyindolacetic acid (5-HIAA) levels. 
Patients and methods 
Between 1992 and 2003, 76 patients were studied; urine was prospectively collected 
over a 24 hours period every 3 months in order to measure urinary 5-HIAA levels. Uni- and 
multivariate analyses were performed. 
Results 
Median follow-up was 55 months with a median survival of 54 months. Prognostic factors 
for poor survival were high age, high gamma-glutamyltransferase levels and greatly 
increased urinary 5-HIAA levels (> 20 mmol/mol creatinine) The Hazard Ratio (HR) of a 
greatly increased urinary 5-HIAA level was 3.33 (95% confidence interval (CI) 1.66-6.66, 
P=0.001). 
In a multivariate survival analysis with the urinary 5-HIAA level as time dependent variable 
the HR for the 5-HIAA level was 1.007 (95% CI 1.004-1.010, P=0.000).  
Conclusion 
In conclusion, patients with persistent low urinary 5-HIAA levels have favourable outcome.  
 





Midgut carcinoid tumours are rare, slowly growing neuroendocrine tumours (NET) 
originating in the small intestine and proximal colon. They are derived from 
enterochromaffin cells and capable of secreting serotonin.1 The World Health 
Organisation nowadays classifies these tumours as well differentiated neuroendocrine 
carcinomas of the small bowel.2 However, the term midgut carcinoid tumour is still being 
used for those tumours originating from the enterochromaffin cells, with serotonin 
secretion and associated with the carcinoid syndrome. In patients with metastatic midgut 
carcinoid tumours an increased urinary 5-hydroxyindolacetic acid (5-HIAA) level, the 
metabolite of serotonin, is found.3 The urinary 5-HIAA level is used as a diagnostic test 
and is used in the evaluation of disease progression and treatment.4,5 Treatment of 
patients with metastatic midgut carcinoid tumours is primarily palliative and aimed at 
ameliorating symptoms, improving quality of life and prolonging survival. This can be 
achieved by somatostatin analogues, interferon (IFN) alpha, targeted radionuclide 
therapy and in selective patients by surgery.6-9 Treatment leads, in the majority of 
patients, to a reduction of the urinary 5-HIAA levels but rarely to objective tumour 
responses. Recently however several targeted drugs such as sunitinib, bevacizumab and 
mTOR inhibitors showed signs of antitumour activity in these tumours.10-14 This raised the 
interest in the course of the disease in order to decide, in the future, when during this 
protracted disease to start which drug.  
Survival varies greatly between these patients and it is difficult to predict the course of an 
individual patient. In a large population based study 5 year survival rate was 44.1% for 
patients with metastatic midgut carcinoid tumours.15 In several studies prognostic factors 
were studied (Table 1).9,15-37 Unfavourable factors for survival are high urinary 5-HIAA 
levels at first visit in referral centres, high plasma Chromogranin A (CgA) levels, the 
presence of liver or lymph node metastases, carcinoid heart disease, tumour size, 
histological grade of differentiation and high age (Table 1). 
With the exception of the study by Turner and colleagues no studies are available that 
focus on biochemical parameters during follow-up to predict survival.34 Therefore, the aim 
of the present study was to determine factors that predict survival of patients with 
metastatic midgut carcinoid tumours at referral and during follow-up with the emphasis 




Table 1.  Previous studies identifying prognostic factor at baseline for survival for patients with midgut carcinoid tumours 
Author No Tumour 
5-year 
survival 
5-year survival rate 
subgroups 
Prognostic factors univariate Prognostic factors, multivariate 
Gatta17 7693 GEP-NETP 47%   
age, time period, histological 
grade of differentiation 
Janson19 256 midgutR 63%  
liver metastases, 5-HIAA (>300 µmol/24 hour), high 
CgA, NPK, age 
age 
Wangberg35 64 midgutR 69%    
Hellman9 314 midgutR 57% 
liver metastases 
median 4.9 year 
resection primary and/or lymph nodes, liver 








 tumour size 








Pape26 254 GEP-NETR 57% ileojejunum 67% tumour size (>2 cm), grade of differentiation  




 ileojejunum 68% tumour site, male gender, age 
age, liver/lymph node 
metastases, male sex 
Turner34 139 midgutR 53%  







age, tumour site, tumour size, depth of invasion, 
liver/lymph node metastases 
age, liver metastases 
Soga32 748 CSP 76% 
digestive 67% 
extra digestive 89% 
  
Westberg36 64 CSR 
CHD + 30% 
CHD - 75% 







age, period of diagnosis age, period of diagnosis 
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Table 1. continued 
 
Author No Tumour 
5-year 
survival 
5-year survival rate 
subgroups 
Prognostic factors univariate 
Prognostic factors, 
multivariate 
Quaedvlieg28 2391 carcinoidP 72% 
GI tumour, distant 
metastases 21% 
 
age, stage, gender, tumour 
site, year of diagnosis 
Kirshbom20 434 carcinoidR 50%* 
midgut, distant metastases 
10 year survival 28% 
  
McDermott25 188 GEP-NETR  small bowel 66% 
male sex, T4 tumour, tumour size, liver/lymph 
node metastases 
male sex, metastases 
Greenberg18 270 carcinoidP  small bowel 66% tumour site, stage age, tumour site, stage 
Lepage21 229 GEP-NETP 43% small bowel 48% age, male sex, stage, curative resection age, tumour site, stage 




 liver metastases 54%   
Saha29 112 GEP-NETR  ileojejunum 30%   
Pellika27 132 CSR 
CHD + 20% 
CHD - 50% 
 CHD  
GEP-NET: gastroenteropancreatic neuroendocrine tumour, GI: gastrointestinal, CS: carcinoid syndrome, CHD: carcinoid heart disease,  








Patients and methods 
 
Patients 
Between January 1992 and December 2003 all patients with a metastatic midgut 
carcinoid tumour who were referred for treatment at the Department of Medical 
Oncology, University Medical Centre Groningen, were studied. The diagnosis of a 
metastatic midgut carcinoid tumour was based on the review of operation reports, the 
pathology specimens, thoracoabdominal computed tomography (CT), 111In-octreotide 
scintigraphy and increased levels of 5-HIAA in a 24 hours urine collection (upper 
reference limit 3.8 mmol/mol creatinine) and/or in increased level of serotonin in 
platelets (upper reference limit 5.4 nmol /109 platelets). Data on gender, age at 
diagnosis, race, metastases at presentation, resection of the primary tumour, the 
presence of flushes and or diarrhoea, the use of somatostatin analogues and/or IFN-
alpha and survival were derived from the carcinoid database of the Department of 
Medical Oncology. This database contains medical information from the first appointment 
at the outpatient clinic and during follow-up of all patients with a midgut carcinoid tumour 
referred since 1987. Patients are regularly seen during follow-up every 3 to 6 months by 
the medical oncologist. An echocardiography is performed at referral and thereafter when 
patients are suspected of having carcinoid heart disease, i.e. complaints of dyspnoea 
and/or oedema, new findings on cardiac auscultation or physical signs of heart failure. In 
this database the patient is anonymous using a unique patient code, only known to one 
dedicated data manager. The database can only be checked through this data manager. 
Last moment of follow-up was February 2007. 
 
Laboratory and biochemical markers 
Serotonin in platelet-rich plasma was determined by high performance liquid 
chromatography (HPLC) with fluorometric detection, expressed in nmol/109 platelets.38 
The upper reference limit of alkaline phosphatase (ALP) was 120 U/l and the upper 
reference limit of gamma-glutamyltransferase (GT) was 50 U/l. The urinary 5-HIAA was 
determined by HPLC with fluorometric detection, in a 24 hours urine collection and 
expressed as mmol/mol creatinine.39  
These data were prospectively collected every 3 to 6 months and put in the carcinoid 
database. 




Differences in survival between groups were analysed using Kaplan Meier survival curves 
and tested with the log rank test. We used the following parameters: gender, the 
presence of liver metastases at referral, resection of the primary tumour prior to referral, 
plasma ALP and plasma GT levels (above or beneath the reference limit) and the urinary 
5-HIAA levels at referral. Patients were grouped according to their urinary 5-HIAA levels 
with a cut-off level of 20 mmol/mol creatinine according to previous reported prognostic 
levels.9,19 Hazard ratios (HR) were calculated using a univariate Cox regression analysis 
with plasma ALP, plasma GT, age and urinary 5-HIAA levels as a continuous variable. 
Since laboratory investigations were determined at presentation, ”survival since referral” 
instead of ”survival since diagnosis” was used in the survival analyses. To study the effect 
of several prognostic factors at presentation we performed a multivariate Cox regression 
analysis including factors related to outcome in the univariate analysis (P<0.1). All 
variables were included in this analysis as continuous variables, the urinary 5-HIAA level 
was also included as a grouping variable. Next to survival after referral we also studied 
the prognostic value of the urinary 5-HIAA levels across time using a Cox Regression 
model with the urinary 5-HIAA level as a time-dependent variable, also including factors 
mentioned above. The urinary 5-HIAA level was evaluated as a 3 monthly measurement. 
If data on the urinary 5-HIAA level was missing (203 (23%) out of 666 measurements), we 
interpolated using the level 3 months prior and 3 months after the missing date. The 
urinary 5-HIAA level 6 months prior to the last moment of follow-up was used to predict 
survival. If the difference between the actual follow-up since referral and the last moment 
of an urine collection was more than 6 months, then the last urinary 5-HIAA level was 
extrapolated. For patients with missing data on urinary 5-HIAA levels for more than 12 
months before the last moment of follow-up, the last follow-up date was determined as 6 
months after the last urine collection. As a consequence these patients were alive at this 
moment of follow-up.  
To determine the effect of the cumulative exposure to serotonin we also used the 
cumulative 5-HIAA level at every moment of follow-up as a time-dependent variable. The 
cumulative 5-HIAA level was calculated as the sum of the separate urinary 5-HIAA levels 
measured every 3 months. All tests were performed two-sided and a P-value of <0.05 
was considered statistically significant. All statistical analyses were performed using 








A total of 76 patients, 33 male and 43 female patients, all Caucasian, were included. 
Table 2 shows the characteristics of patients at referral. 
 
Table 2. Characteristics of patients at referral 
Characteristic  
Mean±SD age at diagnosis – years 59.4±9.6 
Mean±SD age at referral – years 60.7±9.3 
Median duration of complaints before referral – months (range) 20 (1-577) 
Primary tumour site – n (%)  
   Ileum 43 (56.6) 
   Small bowel 4 (5.3) 
   Colon 7 (9.2) 
   Unknown 22 (28.9) 
Presence of liver metastases – n (%) 61 (80.3) 
Complaints – n (%)  
   Diarrhoea 49 (64.5) 
   Flushes 51 (69.9) 
Treatment – n (%)  
   Somatostatin analogues 11 (14.5) 
   Interferon-alpha 1 (1.3) 
Laboratory values  
   Median alkaline phosphatase - U/l (range)  93 (35-401) 
   Median gamma-glutamyltransferase – U/l (range)  41 (12-505) 
   Mean±SD serotonin in platelets – nmol/109 platelets  26.2±10.5 
   Median urinary 5-HIAA level – mmol/mol creatinine (range) 21.0 (1.3-418.4) 
5-HIAA: 5-hydroxyindolacetic acid. 
 
Patients were referred to our hospital after a median duration of disease of 2 months 
(range 0-184 months). The median duration of complaints before referral for patients 
with an urinary 5-HIAA level of ≤ 20 mmol/mol creatinine was 13 months (range 1-577 
months) compared to 26 months (range 1-247 months) for patients with an urinary 5-
HIAA level > 20 mmol/mol creatinine (P=0.229).  
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Nine patients (11.8%) out of 76 patients developed carcinoid heart disease during the 
follow-up. Patients with carcinoid heart disease tended to have higher urinary 5-HIAA 
levels at referral, 52.8 mmol/mol creatinine (range 8.5-252.0 mmol/mol creatinine) 
compared to patients without carcinoid heart disease, 18.6 mmol/mol creatinine (range 
1.3-418.4 mmol/mol creatinine) (P=0.085).  
Sixty-one (80.3%) out of 76 patients had liver metastases at referral. Patients with liver 
metastases tended to have higher levels GT at referral, 42 U/l (range 12-505 U/l) versus 
32 U/l (range 13-118 U/l) (P=0.072) respectively. Plasma ALP levels were 99 U/l (range 
35-401 U/L) and 74 U/l (range 50-177 U/l) (P=0.316) in patients with and without liver 
metastases respectively.  
The median follow-up of all patients was 55 months (range 0.5-143 months). Figure 1 
shows the median urinary 5-HIAA levels during follow-up. 
76     65      51      41      33       26      19      11      7       5
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Figure 1. Median urinary 5-hydroxyindolacetic acid (5-HIAA) levels (mmol/mol creatinine) during 




Survival, univariate testing 
Overall median survival since diagnosis and since referral was 75 months (95% 
confidence interval (CI) 61-88 months) and 54 months (95% CI 42-67 months) 
respectively, with a 5 year survival rate of respectively 56.8% and 48.5% (Figure 2). Age 
as a continuous variable was a prognostic factor with a HR of 1.043 (95% CI 1.014-
1.073, P=0.003). Next to age, GT (HR 1.009; 95% CI 1.004-1.013, P=0.000), ALP (HR 
1.006; 95% CI 1.003-1.010, P=0.001) and urinary 5-HIAA levels at referral (HR 1.004; 
95% CI 1.001-1.006, P=0.003) were prognostic factors for poor survival. Table 3 shows 
the univariate analysis of different characteristics at referral. 
Lowering or raising the cut-off level of the urinary 5-HIAA level did not increase the 
difference in survival between the groups when compared to the difference of 57 months 
for patients with a urinary level of ≤ 20 mmol/mol creatinine and > 20 mmol/mol 
creatinine (Figure 3). 
 
 

















Figure 2. Survival after diagnosis (months) 
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Table 3. Univariate analysis with respect to survival after referral  
Factor No HR 95% CI P Median Survival 
(months) 
95% CI 5 year survival (%) P 
Age (years) 76 1.043 1.014-1.073 0.003     
Gender         
   Male 33 0.786 0.462-1.336 0.372 65 54-77 60 0.670 
   Female 43    51 41-61 40  
Liver metastases         
   Present 61 1.790 0.845-3.789 0.104 52 37-69 45 0.123 
   Not present 15    64 31-97 64  
Resection primary tumour         
   Yes 27 0.606 0.341-1.076 0.087 75 44-107 57 0.084 
   No 49    52 37-68 44  
Gammaglutamyltransferase (U/l)  1.009 1.004-1.013 0.000     
   Normal 47    66 53-79 60 0.026 
   Raised 29    43 23-64 28  
Alkaline phosphatase (U/l)  1.006 1.003-1.010 0.001     
   Normal 59    64 51-77 55 0.063 
   Raised 17    29 23-35 25  
Urinary 5-HIAA level (mmol/mol creatinine)  1.004 1.001-1.006 0.003     
   ≤ 20  37    90 69-111 72 0.000 
   > 20  39    33 29-36 26  
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Figure 3. Survival after referral, difference between patients with urinary 5-hydroxyindolacetic acid 
(5-HIAA) ≤ 20 mmol/mol creatinine and > 20 mmol/mol creatinine 
 
Survival, multivariate testing 
In the multivariate model, age, a greatly increased urinary 5-HIAA level (> 20 mmol/mol 
creatinine) and a raised GT level at referral were independent prognostic factors for poor  
survival. The multivariate analysis is presented in Table 4. Patients with an urinary 5-HIAA 
level of > 20 mmol/mol creatinine at referral had a worse survival compared to patients 
with a urinary 5-HIAA level of ≤ 20 mmol/mol creatinine with a HR of 3.33 (95% CI 1.66-
6.66, P=0.001). 
 
Table 4. Multivariate analysis with respect to survival 
Factor HR 95% CI P 
Age 1.052 1.02-1.084 0.001 
Resection primary tumour 0.581 0.306-1.104 0.097 
Gamma-glutamyltransferase 1.009 1.003-1.015 0.002 
Alkaline phosphatase 1.002 0.997-1.008 0.400 
Urinary 5-HIAA level (mmol/mol creatinine) 1.003 1.000-1.006 0.033 
HR: hazard ratio, CI: confidence interval, 5-HIAA: 5-hydroxyindolacetic acid. 
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Urinary 5-HIAA level as a time dependent variable 
Eleven patients (14%) did not collect urine for measurement of 5-HIAA levels for > 12 
months prior to the last follow-up date. Median difference between the actual follow-up 
and the follow-up until the last urine collection in these patients was 38 months (range 
14-80 months). Five (45.5%) out of 11 patients had a change in vital status; deceased at 
the last follow-up moment of February 2007, but still alive 6 months after the last 
moment of urine collection.  
In the extended multivariate Cox regression analysis the HR of the urinary 5-HIAA level as 
a time dependent variable was 1.007 (95% CI 1.004-1.010, P=0.000). The cumulative 






To our knowledge, this is the first study to demonstrate that the urinary 5-HIAA level is an 
independent prognostic factor both at referral and during follow-up for patients with a 
metastatic midgut carcinoid tumour. Patients with a greatly increased urinary 5-HIAA level 
at referral (> 20 mmol/mol creatinine) had a median survival of 33 months compared to 
90 months for patients with a moderately increased level (≤ 20 mmol/mol creatinine). 
Next to the urinary 5-HIAA level we found that high age and a high GT level at referral 
were independent prognostic factors for a poor survival. An extended multivariate 
analysis identified the urinary 5-HIAA level as an independent predictor for poor survival 
with an HR of 1.007 for each increment of the urinary 5-HIAA level (mmol/mol creatinine). 
The data obtained with a 5 year survival rate of 56.8% are comparable to the survival 
found in previous studies (Table 1) and therefore allows generalisation of our findings. 
Several studies did observe urinary 5-HIAA levels at presentation to be related with 
outcome in univariate analysis but after correction for other factors such as age it did not 
stand out.9,19,34 Our study with a relatively high number of measurements per patient, 
validates the use of the urinary 5-HIAA level during follow-up not only for monitoring the 
effect of therapy but also for predicting survival in an individual patient at any moment 
during follow-up.3,5 The HR of the cumulative 5-HIAA level, as a time dependent variable 




serotonin production is important as previously described by Denney and colleagues for 
the development of carcinoid heart disease.40 A cumulative 5-HIAA level does not seem to 
give additive information in predicting survival. At presentation there seems to be a 
threshold for the urinary 5-HIAA level of 20 mmol/mol creatinine for predicting survival, 
since raising the cut-off level (to the level of 40 mmol/mol creatinine) did not influence 
the difference in survival of 57 months between the groups (data not shown).9.19 
Serotonin has its harmful effects through seven different serotonin receptors, saturation 
of these receptors, could potentially well explain this threshold. 
We observed that GT levels predicted survival, probably as a reflection of the presence, or 
the extent of liver metastases, since GT and ALP rise in the presence of liver 
metastases.41,42 Clancy and colleagues also observed that ALP predicted survival in 
patients with metastatic neuroendocrine tumours.43 Their analysis did not include GT 
levels. A recent study of Formica and colleagues also showed that raised liver enzymes 
were associated with a worse prognosis, including GT but not ALP.44 The HR of the 
presence of liver metastases did not reach statistical significance in our analysis; 
however, we did not collect information on the extent of the liver metastases.  
Our findings might have a number of implications for the clinic. First, since urinary 5-HIAA 
levels are prognostic at every moment during follow-up it seems justified to initiate 
treatment not only for symptoms but also because of greatly increased urinary 5-HIAA 
levels.6,7 In 2 previous studies it was already suggested that somatostatin analogues, by 
lowering serotonin secretion, prolong survival in patients with midgut carcinoid 
tumour.28,34 Secondly when a patient first presents it is often difficult to predict prognosis 
and justify starting antitumour treatment with e.g. the newer tumour agents. In clinical 
trials currently often clear radiological tumour progression is required. However based on 
our observations patients with a high urinary 5-HIAA level might be eligible without proof 
of recent anatomical tumour progression.45 
A limitation has to be mentioned, although this is also true for other prognostic studies. 
Patients with midgut carcinoid tumours also with metastatic disease often present 
following a long patient and doctors delay.5 As a consequence these analyses are based 
on values from the period after referral and not after disease onset.  
In summary our study shows that next to high age and a high GT level at referral, the 
urinary 5-HIAA level is an independent prognostic factor of survival of patients with 
midgut carcinoid tumours both at referral and during follow-up. 
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Carcinoid heart disease 
 
Anouk N.A. van der Horst-Schrivers, A.N. Machteld Wymenga, Elisabeth G.E. de Vries 
 




To the editor 
 
Møller and colleagues (March 13 issue) addressed the topic of progression of carcinoid 
heart disease.1 Serial echocardiography was available in 71 of 273 referred patients. The 
median baseline urinary 5-hydroxyindolacetic acid (5-HIAA) level was in patients with 
carcinoid heart disease 209 mg/24 hour, and without carcinoid heart disease 110 
mg/24 hour, with a relatively short median duration of the syndrome of 1.0 and 1.8 
years, respectively.  
Remarkably, literature data on 5-HIAA levels during the course of this disease are hardly 
available. We therefore analysed patients with carcinoid syndrome referred between 
1985-2002 of whom at least two 5-HIAA levels were measured with a 1 year interval 
(n=73). The median urinary 5-HIAA level gradually increased during follow-up, reaching 
110 mg/24 hour only after 7 years (Figure 1). 
 
 
Figure 1. Course of urinary 5-hydroxyindolacetic acid (5-HIAA) levels in time, median values with 
interquartile range. Numbers in figure denote number of patients. 







































The extreme urinary 5-HIAA levels and the relatively high incidence of carcinoid heart 
disease compared to another recent study suggests that Møller and colleagues have 
studied a highly selected group.2 This underscores that although somatostatin analogues 
did not prevent carcinoid heart disease in their population, effects are not precluded in 
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Serotonin transporter promoter polymorphism predicts 
survival in patients with metastatic midgut carcinoid 
tumours 
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In midgut carcinoid tumour patients, serotonin secretion induces carcinoid syndrome and 
affects survival. Serotonin is taken up by cells by the serotonin transporter (SERT) and 
metabolised to 5-hydroxyindolacetic acid (5-HIAA) by monoamine oxidase A (MAO-A). The 
SERT promoter region has a functional polymorphism (5-HTTLPR), with a short (S, 
functional less active) and long (L) allele. A functional polymorphic region, upstream 
variable number of tandem repeats (uVNTR) is present in MAO-A. We studied whether 
these polymorphisms affect symptoms and overall survival in carcinoid patients. 
Patients and methods 
105 patients with metastatic midgut carcinoid tumours and elevated serotonin 
production were genotyped for 5-HTTLPR and MAOA-uVNTR. Endpoints were presence of 
flushes, diarrhoea and survival. In addition effects of genotypes, age, urinary 5-HIAA and 
liver metastases at first visit on death within 5, 6, 7, 8, 9 and 10 years after referral were 
determined with multiple logistic regression analysis. 
Results  
Patients with S’S’ genotype of 5-HTTLPR (n=29) had a shorter median survival (69.6 
months, 95% confidence interval (CI) 20.8-118.3 months) compared to patients with L’S’ 
(n=49, 114.6 months, 95% CI 49.1-180.1 months) or L’L’ genotypes (n=26, 91.2 
months, 95% CI 41.1-141.2 months) (P=0.01). Survival was not influenced by MAOA-
uVNTR. Patients with the S’S’ genotype of 5-HTTLPR had a greater risk to die within 7 to 
10 years after referral, independent of high age, high urinary 5-HIAA concentrations and 
liver metastases. The different genotypes were not related to the presence of flushes and 
diarrhoea.   
Conclusions 
The S’S’ genotype of 5-HTTLPR is associated with a worse survival in patients with a 
metastatic midgut carcinoid tumour. 
 





Midgut carcinoid tumours are rare well differentiated neuroendocrine tumours originating 
in the small intestine and proximal colon. Midgut carcinoid tumours secrete serotonin 
and other vasoactive amines. When serotonin enters the systemic circulation in high 
concentrations, the carcinoid syndrome develops.1,2 This syndrome is characterised by 
various symptoms including flushes, diarrhoea, and carcinoid heart disease, with diverse 
presentation between patients.3-5 High concentrations of free circulating serotonin are 
harmful and cleared from the plasma by cellular uptake in liver, lung and platelets by the 
serotonin transporter (SERT or 5-HTT). The liver and lung deaminate serotonin by the 
mitochondrial enzyme monoamine oxidase A (MAO-A) and thereafter it is oxidised to 5-
hydroxyindoleacetic acid (5-HIAA) and secreted in the urine (Figure 1).6 
Survival varies greatly between patients with metastatic midgut carcinoid tumours and 5-
year survival rates range from 21%-63%.7-9 The urinary 5-HIAA concentration at 
presentation is a known prognostic factor for survival and lowering serotonin secretion 
appears to improve survival, suggesting that serotonin is partly responsible for the 
mortality in these patients.7,9-11 
Differences in plasma clearance of free serotonin due to genetic variation might explain 
why some patients with minimal tumour burden have symptoms whereas others do not 
despite extensive metastatic disease and why there is a broad range in survival duration 
in these patients. Variation in the expression of the SERT protein is associated with 
various mood disorders since SERT removes serotonin from the synaptic cleft thereby 
terminating its action at the receptor.12 Increased uptake of serotonin by SERT is known 
to stimulate hyperplasia in pulmonary artery smooth muscle cells in patients with primary 
pulmonary hypertension.13  
The promoter region of the SERT gene contains a polymorphic region, a 44-base pairs 
(bp) deletion/insertion (5-HTTLPR).14,15 The 5-HTTLPR consists of a short (S, functional 
less active) and a long variant (L, functional active). In the S variant the transcriptional 
activity of the promoter is reduced which coincided with about 2 times decreased SERT 
protein expression and serotonin uptake in lymphoblast cell lines.14,15 Recently an A-G 
substitution in the L allele was described.16 The LG allele decreases transcriptional activity 
of SERT in lymphoblast cell lines, in the same manner as the S allele does. Thus, 5-





Figure 1. Clearance of free serotonin by liver cell, with sites of the serotonin transporter (SERT) 
and monoamine oxidase A (MAO-A), and different genotypic variants (L: long, S: short)  
 
MAO-A is located on the X chromosome and has a polymorphic region consisting of an 
upstream variable number of tandem repeats (uVNTR-MAO-A). This polymorphism 
consists of 4 variants each with 3 or more repeats of 30 bp. Alleles containing 3.5 or 4 or 
5 repeats (long (L)) are functionally more active in transcriptional activity of the promoter, 
compared to the alleles with 3 (short (S)) repeats.17,18 
These 2 frequent polymorphisms might well affect the clearance of free serotonin and 
thus influence the important, harmful role of free serotonin and affect the morbidity and 
mortality of patients with metastatic midgut carcinoid tumours. Currently there are no 
data available on the role of these polymorphisms in carcinoid patients. We therefore 










5-HTTLPR genotypes  
 
SS    
SLG           S’S’  
LGLG   
 
SLA          S’L’  
LALG    
   
LALA.             L’L’ 
uVNTR genotypes  
  
Male   4/- (L carrier) 
  3/- (S carrier) 
 
Female              4/4 (L carrier) 
  3/4 & 3/5 (SL) 
  3/3 (S carrier)  
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examined the relationship among the polymorphisms of SERT and MAO-A, the presence 
of symptoms of the carcinoid syndrome and survival. 
 
 
Patients and methods 
Patients 
All patients with a metastatic midgut carcinoid tumour and elevated serotonin production 
who were referred for treatment and follow-up to the Department of Medical Oncology of 
the University Medical Centre Groningen between January 1987 and July 2004 were 
eligible for inclusion. The diagnosis was based on the review of surgery reports, pathology 
specimens, thoracoabdominal computed tomography, 111In-octreotide scintigraphy and 
increased 5-HIAA concentrations in 24 hour urine and/or an increased serotonin in 
platelets. The study was approved by the Medical Ethics Committee. All patients gave 
written informed consent. Patients who were deceased were included according to local 
regulations by obtaining DNA from an anonymous serum bank. Data on gender, age at 
diagnosis, race, metastases at presentation, resection of the primary tumour, the use of 
somatostatin analogues or interferon (IFN)-alpha and the presence of carcinoid heart 
disease were derived from the carcinoid database of the Department of Medical 
Oncology. This database contains medical information and information on treatment from 
the first appointment at the outpatient clinic and during follow-up of all patients with a 
midgut carcinoid tumour referred between 1987 and 2004. Patients visit the outpatient 
clinic during follow-up every 3 to 6 months. Treatment consists of removal of the primary 
tumour if possible. Somatostatin analogues are started in patients with complaints of the 
carcinoid syndrome. If tumour progresses or complaints worsen IFN-alpha is 
administered. Carcinoid heart disease is diagnosed by echocardiography, which is 
routinely performed in patients at referral. During follow-up echocardiography is 
performed in case of suspicion of carcinoid heart disease (complaints of dyspnoea 
and/or oedema, new findings on cardiac auscultation or physical signs of heart failure). In 
the database the identity of the patient is anonymously used with an unique patient code, 
only known to one dedicated data manager. The database can only be checked through 







DNA was isolated from freshly taken peripheral EDTA anti-coagulated blood samples 
(alive patients) and from frozen serum and plasma samples, stored at -20 0C (deceased 
patients). Genomic DNA was isolated from whole blood and serum using the QIAamp DNA 
Mini Kit (Qiagen, Venlo, The Netherlands). 
 
Genotyping 5-HTTLPR, including S, LA and LG 
5-HTTLPR genotypes were determined using the HTTp2a and HTTp2B primer set to 
amplify 406 (S) and 450 (L) bp fragments with the polymerase chain reaction (PCR).19 
The LA, LG and S alleles were measured by incubation of the PCR product with the 
restriction enzyme Msp I (New England Biolabs, Westburg, Leusden, The Netherlands) for 
at least 3 hours at 37° C. Msp I cuts the GGCC sequence, resulting in fragments of 329, 
62, and 59 (LA), 174, 155, 62 and 59 bp (LG), and 285, 62 and 59 bp (S) respectively. 
The resulting restriction fragments were separated using a 2% agarose gel and visualized 
using GelStar (SYBR-green; Cambrex Bio Science, Rockland, ME, USA). The triallelic 
genotypes were reclassified into a biallelic model by their level of expression as follows: 
LGS, LGLG, and SS were reclassified as S'S', LAS and LALG were reclassified as L'S', and 
LALA was reclassified as L'L' (Figure 1).16 
 
Genotyping uVNTR region of the MAO-A gene    
MAO-A genotyping was essentially performed as described by Sabol and colleagues.18 
The resulting PCR fragments were separated on a Spreadex EL 800 mini gel (Elchrom 
Scientific AG, Cham, Switzerland), using the SEA 2000 Electrophoresis Apparatus 
(Elchrom) and visualized using GelStar (SYBR-green). 
Since the MAO-A is X-linked we classified the different genotypes as L carrier, LS carrier 
and S carrier (Figure 1).  
 
Symptoms of carcinoid syndrome 
Information regarding the presence of diarrhoea and flushing at first visit was collected 
from the carcinoid database of the Department of Medical Oncology. 
 
Biochemical markers 
Serotonin in platelet-rich plasma (upper reference limit 5.4 nmol /109 platelets) and 
urinary 5-HIAA in a 24 hour urine collection (upper reference limit 3.8 mmol/mol 
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creatinine) were determined by high performance liquid chromatography with 
fluorometric detection as previously described.20 
 
Power analysis  
To determine sample size, we performed a power-analysis based on the primary endpoint 
diarrhoea and 5-HTTLPR as a biallelic allele. We assumed that 50% of patients with the 
LL genotype for 5-HTTLPR had complaints of diarrhoea compared to 80% of patients with 
the LS and 80% of patients with the SS genotype. Among Caucasian individuals the 
frequency of the L allele is 60% and the frequency of the S allele is 40%.15 Group sample 
sizes of 32 were required to detect a 30% difference with a power of 80% between 2 
groups. Therefore, we aimed at collecting 32 patients for each genotype of the three 5-
HTTLPR genotypes, resulting in a total of at least 96 patients.  
We report here the results of the 5-HTTLPR as a triallelic locus as it became clear in 




Differences between groups were tested using one way Anova or Kruskall-Wallis tests for 
continuous variables, and the Chi-square test was performed to test differences for 
categorical variables. Differences in overall survival according to genotypes were 
analysed using Kaplan Meier survival curves and formally tested with the log rank test. To 
study the independent effect of genotypes on overall survival we performed multiple 
logistic regression analyses with the outcome death within 5, 6, 7, 8, 9 respectively 10 
years after referral. We adjusted for the urinary 5-HIAA concentration at referral (as a 
continuous variable), age at referral (as a continuous variable) and the presence of liver 
metastases. Since the urinary 5-HIAA concentrations, age and the presence of liver 
metastases were determined at referral, the ‘death within 5, 6, 7, 8, 9 respectively 10 
years after referral’ instead of ‘ death within 5 to 10 years after diagnosis’ was used in 
these survival analyses. All tests were performed two-sided and a P value of <0.05 was 







A total of 105 (96.3%) out of 109 eligible patients, all Caucasian, were included. In 87 
(82.9%) patients pathology reports showed tumours with low grade malignancies. The 18 
(17.1%) patients in whom no pathology was available had a median survival of 129.5 
months and are thus also regarded as low grade malignancies.  
Four patients could not be genotyped for the uVNTR-MAO-A and 5 patients not for 5-
HTTLPR due to limited availability of DNA. Median follow-up of all patients since diagnosis 
was 55.7 month (range 0.4-281.1 months).   
Patient characteristics and allele frequencies for the different genetic variants of the 5-
HTTLPR and the uVNTR-MAO-A are presentated in Table 1. All polymorphisms were in 
Hardy-Weinberg equilibrium.  
There were no statistically significant differences between different genetic variants with 
respect to patient characteristics at referral. Patients with the S’S’ variant of the 5-
HTTLPR tended to have lower urinary 5-HIAA concentrations at referral (22.0 mmol/mol 
creatinine, range 1.3-166.2 mmol/mol creatinine) compared tot patients with the L’S’ 
(30.6 mmol/mol creatinine, range 2.5-418.4 mmol/mol creatinine) and the L’L’ variant 
(23.5 mmol/mol creatinine, range 3.2-271.6 mmol/mol creatinine) (P=0.1).  
Ten patients (9.5%) were using somatostatin analogues and 2 patients (1.9%) IFN-alpha 
at referral.    
 
Symptoms of carcinoid syndrome 
Flushes and diarrhoea were present in respectively 79 (75.2%) and 66 (62.9%) out of 
105 patients at referral. There were no differences in the presence of flushes or 
diarrhoea between the different genotypes of the 5-HTTLPR or the uVNTR-MAOA (Table 
2). Symptomatic carcinoid heart disease, confirmed with echocardiography, developed in 
15 (14.3%) out of 105 patients during follow-up. Seven (26.9%) out of 26 patients with 
the L’L’ genotype developed carcinoid heart disease compared to 4 (8.2%) out of 49 
patients in L’S’ and 4 (13.8%) out of 29 patients in the S’S’ genotypic group (P=0.09). 
 
Survival 
Median overall survival since diagnosis was 77.7 months (95% confidence interval (CI) 
59.2-96.2 months). Five and 10 year survival rates were 58.8% and 32.9% respectively. A 
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total of 77 patients (73.3%) died during follow-up. The median overall survival of the S’S’ 
genotype was 69.6 months (95% CI 20.8-118.3 months) compared to a median overall 
survival of the L’S’ and the L’L’ genotype of 114.6 months (95% CI 49.1-180.1 months) 
and 91.2 months (95% CI 41.4-141.2 months) respectively (P=0.01) (Figure 2). Ten year 
survival rates were 17.1% for patients with the S’S’ genotype, 49.6% for patients with the 
L’S’ genotype, and 28.2% for patients with the L’L’ genotype. 
 


























Figure 2. Kaplan-Meier survival curve from time of diagnosis for the different genotypic variants of 




      L’L’     25       24        21       17        13         12       9          8 6           5 
   
      L’S’     45       41        31       27         24       21       20       18       17      15 
   
      S’S’    26        22        18       15        13        12       7         4          3          2 
 




Table 1. Basic characteristics at referral of patients for the different genotypic variants of the 5-HTTLPR and the uVNTR region of the MAO-A gene 
 5-HTTLPR uVNTR 
 L’L’ L’S’ S’S’ P L carrier S carrier LS P 
Number of patients  26 (25.0) 49 (47.1) 29 (27.9)  50 (47.6) 31 (29.5) 24 (22.9)  
Sex male  11 (42.3) 23 (46.9) 10 (34.5) 0.60 22 (44.0) 22 (71.0) 0 (0.0) <0.00
1 Mean±SD age at diagnosis – years 57.2±9.4 57.7±11.7 61.7±9.7 0.18 59.3±9.9 56.5±12.9 60.1±9.2 0.39 
Tumour resection  13 (50.0) 17 (34.7) 12 (41.4) 0.43 22 (44.0) 10 (32.2) 12 (50.0) 0.38 
Liver metastases  19 (73.1) 39 (79.6) 25 (86.2) 0.48 41 (82.0) 27 (87.1) 15 (62.5) 0.07 














  0.15 
Data are numbers (%) unless otherwise indicated. 5-HTTLPR: serotonin transporter gene–linked polymorphic region, uVNTR: upstream variable number of tandem 




Table 2. Presence of flushes and diarrhoea at referral and overall survival since diagnosis between the different genotypic variants of the 5-HTTLPR 
and the uVNTR region of the MAO-A gene  
Outcome 5-HTTLPR uVNTR 
 L’L’ L’S’ S’S’ P L carrier S carrier LS P 
Flushes  19 (73.1) 37 (75.5) 21 (72.4) 0.98 35 (70.0) 26 (83.9) 17 (70.8) 0.48 
Diarrhoea  16 (61.5) 31 (63.3) 17 (58.6) 0.73 26 (52.0) 19 (61.3) 19 (79.2) 0.12 














Data are numbers (%) unless otherwise indicated. 5-HTTLPR: serotonin transporter gene–linked polymorphic region, uVNTR: upstream variable number of tandem 
repeats, MAO-A: monoamine oxidase-A, CI: confidence interval. 
                                                                                                      Polymorphism of SERT and MAO-A 
 
67 
In the multiple logistic regression analysis with the outcome death within 5 years after 
referral, high age was a prognostic factor for dying. In the multiple logistic regression 
analysis with the outcome death within 6 to 10 year after referral, the S’S’ genotype of 
the 5-HTTLPR, high age and high urinary 5-HIAA concentrations were independent 
predictors when the outcome was dying within 7, 8, 9 and 10 years after referral. Patients 
with the L’S’ genotype had a better overall survival compared to patients with the S’S’ 
genotype. Patients with the S’S’ genotype had an increased risk to die within 10 years 
after referral (Odds Ratio (OR)=4.36 (95% CI 1.33-14.30, P=0.02) compared to patients 
with the L’S’ genotype. The OR for patients with the S’S’ genotype compared to patients 
with the L’L’ genotype was 1.64 (95% CI 0.43-6.23, P=0.47). The OR for dying within 6, 7, 
8 and 9 years within referral of patient with the S’S’ genotype compared to patients with 
the L’S’ genotype was 1.86 (95% CI 0.64-5.42, P=0.26), 3.26 (95% CI 1.04-10.26, 
P=0.04), 3.06 (95% CI 1.00-9.30, P=0.05) and 4.65 (95% CI 1.43-15.18, P=0.01) 
respectively. Including the uVNTR-MAO-A into the model did not affect these results. 
Median overall survival of the different genotypes of the uVNTR-MAO-A is presented in 






This study shows that patients with a metastatic midgut carcinoid tumour and the S’S’ 
genotype of 5-HTTLPR have a worse overall survival compared to the patients with the 
L’L’ and L’S’ genotypes. No association was observed between the different genotypic 
variants of the 5-HTTLPR and symptoms of flushes or diarrhoea at the moment of 
referral.    
The association between the genotypes of 5-HTTLPR and death after referral from 7 
years onwards is independent of other known risk factors for a worse survival, such as 
high age, high urinary 5-HIAA concentrations and the presence of liver metastases.7,9 It is 
also independent of the uVNTR polymorphism of MAO-A.   
The median survival of our population is comparable with the survival rates reported in 
previous studies with patients with midgut carcinoid tumours.7,8,21  To our knowledge this 




metastatic midgut carcinoid tumours. No interest in these genes contrasts with the 
research performed in other diseases such as several psychiatric disorders. A body of 
evidence exists on the relation between the 5-HTTLPR polymorphism and a disturbance 
in the neurotransmission of serotonin.15,16,22 Outside the central nervous system 5-
HTTLPR polymorphism is associated with the development of primary pulmonary 
hypertension and it has been suggested as a potential gene involved in the irritable bowel 
syndrome.13,23,24 
The relation between 5-HTTLPR polymorphism and survival in patients with a metastatic 
midgut carcinoid tumour can be explained by several mechanisms. The S and Lg alleles 
have lower transcriptional activity, leading to a lower expression of SERT in cells with the 
S’S’ variant.15,16 Hence patients with the S’S’ genotype are likely to be exposed to free 
circulating serotonin for a longer period of time. This is of clinical importance since 
patients with metastatic carcinoid tumours have high free serotonin levels.25 
Free serotonin has several harmful acute and chronic cardiovascular effects.26 The 
prominent cardiovascular effect of serotonin in patients with metastatic midgut carcinoid 
tumours is the fibrous thickening of the heart valves, also known as carcinoid heart 
disease, leading to right sided heart failure and early death.27-29 There is clear evidence 
for the causal role for serotonin in the development of carcinoid heart disease. Rats who 
received serotonin injections for 3 months developed lesions comparable to those seen 
in carcinoid heart disease.30 Patients using fenfluramine, a sympathomimetic amine that 
activates serotonergic pathways also formed such fibrous thickening of the heart 
valves.31 In addition a recent study showed that mice deprived of their SERT (SERT- knock 
out), were prone to develop fibrosis and functional alteration of the heart.32 We found a 
slightly higher prevalence of clinical carcinoid heart disease in patients with the L’L’ 
genotype, this did however not reach statistical significance. This may be due to too low 
number of patients with carcinoid heart disease in our study and needs to be evaluated 
in a larger population.  
In clinical practice if our results are confirmed in other series, genotyping patients with a 
metastatic midgut carcinoid tumour for the 5-HTTLPR may be of value to identify patients 
at risk for poor survival. This could lead to a more tailored approach in patients with the 
S’S’ genotype of the 5-HTTLPR e.g. by using early somatostatin analogues, or newer 
targeted drugs such vascular endothelial growth factor inhibitors.33-35  
In conclusion the S’S’ genotype of the 5-HTTLPR is associated with a shorter survival in 
patients with metastatic carcinoid midgut carcinoid tumours. 
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Established systemic treatment choices for metastatic neuroendocrine tumours (NETs) 
are somatostatin analogues and alpha interferons (IFN-alpha) both reducing the secretory 
activity of the tumour. IFN-alpha also has an anti-proliferative effect, inhibiting 
angiogenesis, blocking the cell cycle, and stimulating apoptosis.1 Chemotherapy has 
limited value, used in NETs with a high-proliferative index.  
Angiogenesis has raised interest as a new target in NETs. This interest is fuelled by the 
fact that NETs are highly vascularised and vascular endothelial growth factor (VEGF) and 
its receptors are present.2 We performed a study with IFN-alpha, 5-fluorouracil (5-FU) and 
leucovorin in patients with metastatic NETs because of the suggested synergistic effects 
between 5-FU and IFN-alpha, and promising results of this combination obtained by 
others.3 In this feasibility study, approved by the Medical Ethical Committee, patients 
were treated with IFN-alpha-2b (2.5 million U/day subcutaneously), and after 2 weeks, 
intravenous 5-FU 750 mg/m2 (day 2) and oral leucovorin 180 mg/day (day 1 and 2) were 
added as a 2 weekly cycle. 
The primary endpoint was toxicity, the secondary endpoints included radiological and 
biochemical response. In addition, serum was prospectively stored for serum VEGF level 
measurements.  
This study was prematurely closed after 9 patients because of side effects. After 1 cycle, 
3 patients had to stop, because of grade 3 fatigue (n=2) and heart failure (n=1). Three 
additional patients discontinued after respectively 2, 3 and 4 cycles because of arthritis 
and polyneuropathy (n=1) and grade 3-4 diarrhoea and fatigue (n=2). The remaining 3 
patients completed 10, 19 and 20 cycles. Median survival was 22 months, 2 patients are 
still alive after 144 months. All 3 radiological evaluable patients experienced stable 
disease lasting 5 - 84+ months.  
Serum VEGF levels (R&D Systems, Minneapolis, USA) decreased in 7 out of 8 evaluable 
patients, from a median level of 352 pg/ml (range 41-1276 pg/ml) to 219 pg/ml (range 
18-938 pg/ml), a median reduction of 40% in 88 days (median) (range 34-462 days). 
This suggests an antiangiogenic effect of the combination IFN-alpha and 5-FU. One study 
showed that IFN-alpha alone did not reduce serum VEGF levels in patients with carcinoid 
tumours, although it did in another study (median reduction 33%) also decreasing VEGF 
mRNA expression in liver metastases.1,4 
In the present study toxicity was considerable. Next to the synergistic effect of this 
regime, IFN-alpha also can potentiate the toxicity of 5-FU.  Four different dosages of 5-FU 
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and INF-alpha were previously studied in patients with NETs, only the regimen in a study 
of Andreyev and colleagues was well tolerated in which 5-FU was given continuously.3  
Bevacizumab, a monoclonal antibody against VEGF was found to prolong progression free 
survival compared to IFN-alpha in carcinoids while sunitinib, a tyrosine kinase inhibitor, 
induced stable disease in NETs.5,6 Recently Zhang and colleagues showed that 
bevacizumab inhibited tumour growth in carcinoid xenograft, but at the same time up 
regulation of VEGF transcription occurred as a possible resistance mechanism.2 During 
sunitinib therapy elevated baseline serum VEGF also increased, possibly due to 
resistance.7 
We conclude that this combination of 5-FU and IFN-alpha is not feasible due to side 
effects. However taken our observation of decreased VEGF levels, less toxic 
modifications, e.g. 5-FU given continuously or IFN-alpha combined with capecitabine, an 
oral fluoropyrimidine prodrug, in combination with one of the new antiangiogenic drugs 
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Sexual dysfunction is a poorly studied aspect of Quality of Life (QoL) in patients with 
midgut carcinoid tumours. We investigated whether carcinoid patients experience sexual 
problems. 
Patients and methods 
Patients with metastatic midgut carcinoid tumours filled in a validated questionnaire for 
screening of sexual dysfunction (QSD). The prevalence of sexual dysfunction on the 
subscales arousal, erection, lubrication, orgasm and dyspareunia, was compared to a 
Dutch reference population. Plasma concentrations of gonadal hormones, tryptophan 
and urinary 5-hydroxyindolacetic acid (5-HIAA) concentrations (µmol/24 hours) were 
measured.  
Results 
Forty three patients were studied, 27 men, mean±SD age 61.8±8.3 years and 16 
women, mean±SD age 58.5±10.2 years. Sexual dysfunction was present in 29.6% of 
men (n=8) and in 6.3% of the women (n=1). The prevalence of sexual dysfunction on the 
different subscales did not differ from the reference population. Male patients with a 
sexual dysfunction had, compared to those without a sexual dysfunction, a longer 
duration of disease, namely 95.3 months (range 5.4-314.5 months) versus 18.6 months 
(range 0.6-167.9 months) (P=0.024), lower plasma tryptophan concentrations (±SD) of 
respectively 31.5±16.1 µmol/L and 48.9±14.5 µmol/L (P=0.031), and used more 
frequently interferon-alpha, respectively 4 out of 8 patients (50%) and 2 out of 19 
(10.5%) (P=0.044). 
Conclusion 
Patients with metastatic midgut carcinoid tumours do not experience sexual problems 
more often than a reference population. Male patients with sexual dysfunction are 
characterised by a more longstanding disease and lower tryptophan concentrations.  





Sexual dysfunction is a common problem in patients with cancer, that can affect their 
quality of life (QoL).1 Few studies evaluated the QoL of patients with midgut carcinoid 
tumours.2-4 Only one study in the early seventies specifically studied sexual dysfunction.5 
In this study in 16 carcinoid patients, including 10 male patients with the carcinoid 
syndrome and elevated urinary 5-hydroxyindolacetic acid (5-HIAA) concentrations, a 
decrease in libido after the onset of the disease was observed.5 In another study, 
investigating the QoL in carcinoid patients, distress about possible changed sexual 
function was present in 13 (36%) out of 37 patients, although this was evaluated with 
just one single question.2    
Several factors could potentially play a role in a changed sexual function in patients with 
a midgut carcinoid tumour. First, serotonin changes in the brain have been reported to 
interfere with sexual desire, arousal and orgasm.6 Previous data suggest that patients 
with midgut carcinoid tumours have a serotonergic dysfunction due to peripheral 
consumption by the tumour of the precursor tryptophan.7 Second, serotonin and other 
factors have vasoactive properties which can lead to endothelial dysfunction and can 
interfere with the erectile function.8,9 Furthermore, patients can suffer from pain and 
fatigue and often medication is used that may affect the ability to and the desire for 
sexual activity.1,8       
In this study we investigated the sexual function of patients with metastatic midgut 
carcinoid tumours. To gain more insight in the pathogenesis of sexual dysfunction in this 
population and for hypotheses generation for possible future treatment strategies, we 
also evaluated the biochemical activity of the tumour and gonadal hormone 
concentrations in relation to sexual function. 
 
 
Patients and methods 
 
Patients 
Patients with metastatic midgut carcinoid tumours were recruited in 4 Dutch hospitals: 
the University Medical Centre Groningen (UMCG) in Groningen, the Erasmus Medical 




West Friesch Gasthuis in Hoorn. Inclusion criteria were: (1) Diagnosis of a midgut 
metastatic carcinoid tumour based on the review of surgery reports, histology specimens, 
thoracoabdominal computed tomography, 111In-octreotide scintigraphy and increased 
concentrations of 5-HIAA in a 24 hour urine collection and/or in increased level of 
serotonin in platelets, (2) life expectancy of more than 3 months, and (3) age 18 years or 
older. All eligible patients were informed about the purpose and the character of the 
study. Participating patients received the questionnaires, which they returned by mail. 
Information on the duration of the carcinoid tumour, the use of somatostatin analogues 
and/or interferon (IFN)-alpha were derived from the medical charts.  
Patient’s data on medical history with emphasis on co-morbidity, smoking and medical 
therapy, were obtained through a questionnaire. All patients gave written informed 
consent. The questionnaires were only marked by a study number and entered in a 
database by a data manager not involved in routine patient care. The study was approved 
by the Medical Ethics Committees of all hospitals. 
 
Questionnaire on sexual dysfunction  
The short version of the Questionnaire for screening Sexual Dysfunction (QSD) was used 
to measure sexual function.10 This questionnaire assesses the frequency and 
experienced distress of sexual problems on different subscales, e.g. orgasm, erection, 
arousal, pain. Different versions for men and women, relationship status and sexual 
orientation are available. Research on the validity of this instrument is available.10 
Frequencies of sexual problems are rated on a five point ordinal scale, ranging from 
almost never (score 1) to always (score 5). Experienced distress accompanying these 
problems is also rated on a five point scale from no distress (score 1) to severely stressful 
(score 5). We defined a sexual problem as clinically relevant or as a dysfunction when 
scores on the frequency or experienced distress scale were 3 or higher. This means that 
a sexual problem is experienced ‘regularly’ to ‘always’ and the distress with this problem 
is scored as ‘stressful’ to ‘severely stressful’. We selected the subscales concerning 
problems with sexual arousal, erection, orgasm and ejaculation for male patients and the 
subscales concerning problems with sexual arousal, lubrication, orgasm and dyspareunia 
for female patients. Satisfaction is scored on a five point scale ranging from very 
dissatisfied (score 1) to very satisfied (score 5). To compare the results of patients with 
midgut carcinoid tumours to the general population we used data from the Rutger Nisso 
Foundation, who used the QSD in a random Dutch population.11  
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Health related QoL 
Health related QoL was assessed using the Dutch version of the European Organization 
of Research and Treatment of Cancer (EORTC) QoL-Core 30 Questionnaire (QLQ-C30).12 
This questionnaire has five functional scales: physical, role, cognitive, emotional and 
social functioning and three symptom scales: fatigue, pain and nausea and vomiting. This 
questionnaire has also six single-item questions about dyspnoea, insomnia, loss of 
appetite, constipation, diarrhoea, and financial difficulties; and two questions about 
global health and QoL. Answers on the questions range from not at all (score 1) to very 
much (score 4). Answers on the items for the global health/quality of life scale range from 
very poor (score 1) to excellent (score 7). Scores were transferred to a score from 0 to 
100, according to the EORTC QLQ-C30 scoring manual.13 A high score for the 
symptom/item scales represents a high level of symptoms/problems, whereas a high 
score for the functioning scales and the global health or general QoL scales represents a 
high level of functioning, global health or general QoL. 
 
Laboratory investigations 
Urine and blood samples were taken within 2 months after the questionnaires were 
returned. 
Urinary 5-HIAA was determined with HPLC with fluorometric detection.14,15 All urinary 5-
HIAA concentrations were expressed in µmol/24 hours (normal range 14.7-97.2 µmol/24 
hours). Plasma tryptophan was measured as previously described.16 Serum testosterone 
was measured by a Radio-immuno-assay (lower reference value 12 nmol/L). Luteinizing 
hormone (LH) and follicle stimulating hormone (FSH) were determined by an Enzyme 
Immuno Assay. Free testosterone was calculated from serum total testosterone using sex 
hormone-binding globulin (SHBG) and the albumin serum concentration (reference value 
in male patients 300-650 pmol/L).17  
 
Statistical analysis 
The prevalence of sexual dysfunction on the different subscales is descriptive.  
In 2006, the prevalence of sexual dysfunction using the same QSD in the general Dutch 
population (reference population), age up to 69 years, became available.11 However in 
this reference population not all questions for the different subscales were included. 




our patients with midgut carcinoid tumours. For comparison between prevalences of 
sexual dysfunction on different subscales we used a Chi-square test or Fisher exact test 
as appropriate.  
Since not all questions belonging to a subscale were asked in this reference population, 
we recalculated the prevalence of dysfunction in our patients using only those questions 
that were asked in the population study.  
To compare patients with and without sexual dysfunction, we used t-tests for normally 
distributed variables, the non-parametric Mann-Whitney U test for variables not normally 
distributed and a Fisher’s exact test for differences for categorical variables. P values 







A total of 43 (78.2%) out of 55 eligible patients returned the questionnaire, 27 men, 26 
with a female partner and 1 man without a partner and 16 women, 9 with a male partner 
and 7 without a partner. Baseline demographic and clinical characteristics are presented 
in Table 1. Mean±SD age was 61.8±8.3 years in male patients and 58.5±10.2 years in 
female patients.  
 
Questionnaire for sexual dysfunction 
The prevalence of sexual dysfunction in male and female patients with carcinoid tumours 
is shown in Table 2. The prevalence of sexual dysfunction in male patients regarding 
sexual arousal, orgasm and erection in our study population was 22.2% (n=6), 14.8% 
(n=4) and 25.9% (n=7) respectively. Nineteen (70.4%) out of 27 men did not have a 
sexual dysfunction on any of the selected subscales. None of the male patients reported 
ejaculation problems. Only one (6.3%) woman reported an orgasm dysfunction, no other 
problems were reported by the female patients in this study. 
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Male 27 (62.8) 
Male patients with female partner 26 (96.3) 
Female patients with male partner 9 (56.3) 
Mean±SD age – years 60.6±8.8 
Median time since diagnosis – months (range) 27 (1-314) 
Liver metastases 37 (90.2) 
Medical therapy  
        Somatostatin analogues 31 (77.5) 
        Interferon-alpha 7 (17.5) 
Symptoms of carcinoid syndrome  
        Diarrhoea 21 (53.8) 
        Flushes 20 (50.0) 
Median urinary 5-HIAA concentration – µmol/24 hour (range) 599 (24-5102) 
Medical history  
        Diabetes 5 (11.6) 
        Surgery pelvic region 9 (20.9) 
Intoxication     
        Smoking 4 (9.3) 
Use of medication  
        Beta blocker 12 (27.9) 
        ACE inhibitor and/or AT II antagonist 11 (25.6) 
        Benzodiazepines  2 (4.7) 
        Calcium channel blocker 3 (7.0) 
        Spironolactone 3 (7.0) 
        Tricyclic antidepressant 1 (2.3) 
        Progesterone 1 (2.3) 
Data are numbers (%) unless otherwise indicated. 5-HIAA: 5-hydroxyindolacetic acid, ACE: angiotensin 









Table 2. Prevalence of sexual dysfunction of different subscales in patients with metastatic 
midgut carcinoid tumours 
 
Male patients Female patients 
Patients  27 16 
Sexual arousal 6 (22.2) 0 (0.0) 
Orgasm 4 (14.8) 1 (6.3) 
Erection 7 (25.9)  
Ejaculation 0 (0.0)  
Lubrication  0 (0.0) 
Pain  0 (0.0) 
Mean±SD satisfaction score 2.92±1.03 3.60±0.95 
Data are numbers (%) unless otherwise indicated. 
 
Comparison with reference population  
The age range in the reference population was 52-69 years in men (n=583, weighted for 
age) and 44-69 years for women (n=1032, weighted for age). The prevalence of sexual 
dysfunction in male patients using only those questions that were asked in the reference 
population, was 3.9% (n=1) regarding arousal, 25.9% (n=7) regarding erection and 
11.1% (n=3) regarding the orgasm. Table 3 shows the prevalence of sexual dysfunction in 
the reference population compared to patients with metastatic carcinoid tumours. No 
statistical significant differences were found between male or female patients and the 
reference population.  
 
Table 3. Frequencies of sexual dysfunction in different subscales in patients with metastatic 
midgut carcinoid tumours compared to the reported prevalence (%) in a Dutch population 
(reference population) 
 Male References P Female References P 
Patients  27 583  16 1032  
Sexual arousal 1 (3.7) 10 (1.7) 0.38 0 (0.0) 36 (3.5) 1.00 
Orgasm 3 (11.1) 29 (5.0) 0.15 1 (6.3) 87 (8.4) 1.00 
Erection 7 (25.9) 96 (16.5) 0.18    
Lubrication    0 (0.0) 88 (8.5) 0.39 
Pain    0 (0.0) 45 (4.4) 1.00 
Data are numbers (%). 
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Patients with and without sexual dysfunction  
Only one woman reported orgasm problems, therefore a comparison between female 
patients with and without sexual dysfunction was not made. Eight male patients (29.6%) 
were defined to have a sexual dysfunction and were compared to the 19 male patients 
who experienced no problems on the selected subscales (Table 4). 
 
Table 4. Male patients with metastatic midgut carcinoid tumours, comparison of patients with and 
without sexual dysfunction 
 
Sexual dysfunction No sexual dysfunction P 
Patients  8 (29.6) 19 (70.4)  
Mean±SD age – years 60.3±5.4 62.4±9.2 0.54 
Median duration disease – months (range) 95.3 (5.4-314.5) 18.6 (0.6-167.9) 0.024 
Median Ur 5-HIAA – µmol/24 hour (range) 872.5 (55.1-3806.0) 259.0 (24.3-2376.2) 0.163 
Mean±SD tryptophan – µmol/L 31.5±16.1 48.9±14.5 0.031 
Medical therapy    
     Somatostatin analogues 7 (87.5) 15 (78.9) 1.00 
     Interferon 4 (50.0) 2 (10.5) 0.044 
     Beta blocker 1 (12.5) 3 (15.8) 1.00 
Mean±SD total testosterone – nmol/L 14.0±5.3 15.4±5.4 0.53 
Median LH –U/L (range) 4.80 (2.43-21.30) 5.22 (2.35-18.7) 0.90 
Median FSH – U/L (range) 8.23 (1.66-28.7) 6.61 (2.4-28.90) 0.69 
Data are numbers (%) unless otherwise indicated, 5-HIAA: 5-hydroxyindolacetic acid; ur: urinary; LH: 
luteinizing hormone; FSH: follicle stimulating hormone  
 
In male patients who reported a sexual dysfunction, the disease duration was 
significantly longer 95.3 months (range 5.4-314.5 months) compared to patients who did 
not reported sexual dysfunction, 18.6 months (range 0.6-167.9 months) (P=0.024). Male 
patients with sexual dysfunction also had lower plasma tryptophan concentrations (±SD) 
compared to patients without sexual dysfunction, respectively 31.5 (±16.1) µmol/L and 
48.9 (±14.5) µmol/L (P=0.031). Plasma concentrations of total testosterone and 
gonadotrophins did not differ between patients with and without a sexual dysfunction. 
Mean total testosterone (±SD) concentration in the all 27 male patients was 15.9 (±5.9) 
nmol/L. Seven (25.9%) out of 27 men had a total testosterone concentration below the 
reference level of 12 nmol/l. In contrast to other laboratory investigations, free plasma 




(42.9%) out of 21 male patients had a free testosterone concentration below the 
reference level of 300 pmol/L.  
 
Quality of life  
The summary of the EORTC QLQ-C30 is presented in Table 5. The Global QoL score 
tended to be lower in male patients with sexual dysfunction compared to male patients 
without sexual dysfunction, respectively 52.1±18.2 versus 62.7±19.3 (P=0.20).   
 
Table 5. Summary of EORTC-C30 in patients with metastatic midgut carcinoid tumours 
Domain Score 






Global QoL 61.8±21.8 










Financial impact 10.1±23.6 
Data are mean±SD. QoL: Quality of Life.  
Note. Scores range from 0 to 100. A high score for the symptom/item scales represents a high level of 
symptoms/problems, a high score for the functioning scales and the global health or general QoL scales 
represents a high level of functioning or general QoL. 





In our study 29.6% of male patients with a metastatic midgut carcinoid tumour and 
elevated serotonin production reported a clinical relevant sexual problem concerning 
arousal, erection or orgasm. The prevalence of sexual dysfunction on the different 
subscales was however for all carcinoid patients studied similar to a Dutch reference 
population.11 Only one woman in our population reported sexual dysfunction. This low 
prevalence could be an underestimation, because 7 out of 16 women were not involved 
in a relationship. According to the QSD, a person not sexually active is defined as having 
not a sexual dysfunction. In addition in women, feelings of intimacy are often more 
important than feelings of sexual arousal, in particular when dealing with illness. In men 
sexual dysfunction is more visible and thus classified by men as a problem.8 
In 1974 Feldman et al were the first to study the sexual function of patients with a 
carcinoid tumour.5 We can not compare our data properly with Feldman’s as they did not 
used a specific questionnaire. However 5 (50%) out of 10 male patients in their study 
with a carcinoid syndrome had almost a complete impotence. The urinary 5-HIAA 
concentration in the patients studied by Feldman was higher (mean 835 µmol/24 hour) 
so maybe they studied patients with more extensive disease, explaining the higher 
prevalence of sexual dysfunction.  
In accordance with the definition of sexual dysfunction by the DSM IV, the QSD, which 
was used in our study, explicitly takes into account the experienced burden or distress by 
patients.18 This is necessary for a proper judgment of sexual dysfunctions. Data from 
population studies are also difficult to compare. They use different questionnaires and do 
not always take into account this experienced distress.19,20 This underscores the 
necessity to unify the tools for investigation of sexual dysfunction.    
Mean plasma tryptophan concentrations were lower and median urinary 5-HIAA 
concentrations tended to be higher in 8 male patients with sexual dysfunction. This could 
be explained by the fact that patients with sexual dysfunction represent the patients with 
a more extensive and longstanding disease and therefore are more affected by sexual 
dysfunction.8 In a recent study of Lindau and colleagues who investigated sexuality and 
sexual problems in 3005 US adults between 57 to 85 years of age, respondents who 




Although male patients with midgut carcinoid tumours have increased levels of plasma 
serotonin, only 7 out of 27 complained of erectile dysfunction. It would be of interest to 
study the effect of doxazosin and ketanserin in male patients with midgut carcinoid 
tumours and erectile dysfunction to investigate whether blocking the serotonin receptor 
inhibits the effect of serotonin on the contraction in the cavernosal tissue, during the 
erection.22    
Our data indicate that the use of IFN-alpha may be associated with sexual dysfunction. 
The influence of IFN-alpha on sexual dysfunction was previously noted in patients with 
hepatitis C treated with IFN-alpha and was explained by lower testosterone 
concentrations.23 Total testosterone concentration were also lower in our patients treated 
with IFN-alpha, however testosterone concentrations did not differ between patients who 
reported sexual dysfunction and patients who did not report problems.  
Hypogonadism was a frequently occurring condition (in 64% of patients) in a recent study 
in 48 male patients with advanced cancer.24 In our population free plasma testosterone 
concentrations were low (< 300 nmol/L) in about 41% and total testosterone 
concentrations were below the reference level in about 26% of the male patients. The 
reference range for free plasma testosterone was obtained in men aged 20 to 54 years 
while our patients were older and these levels tend to decline during life.25 The underlying 
mechanism of low testosterone concentrations is unclear, but next to the influence of 
IFN-alpha, factors secreted by the carcinoid tumours could play a role. Tachykinins have 
been shown to inhibit the release of testosterone in vitro.26 Patients might benefit from 
testosterone replacement not solely for improvement of sexual function but also for 
overall well-being.1, 27 
Ratings on the health related QoL were comparable to those previously reported in 
patients with midgut carcinoid tumours.2,3 The global QoL tended to be lower in patients 
with sexual dysfunction however this was not statistical significant and it can not be ruled 
out that this is due to more advanced disease.   
Overall, our results show that about 30% male patients with midgut carcinoid tumours 
experience sexual dysfunction, which is comparable to the general population. However, 
physicians should be aware that sexual dysfunction in patients with midgut carcinoid 
tumours occurs, especially in case of longstanding disease, with low plasma tryptophan 
concentrations and during IFN-alpha use. 
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Recommendations on the use of 123iodine(I)-metaiodobenzylguanidine (MIBG) 
scintigraphy in localising phaeochromocytomas vary. We determined the accuracy of 123I-
MIBG scintigraphy by evaluating our own 123I-MIBG scans and performing a meta-
analysis. 
Patients and methods 
Between January 1992 and May 2002, the 123I-MIBG scans of consecutive patients 
suspected of a phaeochromocytoma were re-evaluated. For the meta-analysis, we 
selected studies with more than five 123I-MIBG scans.  
Results 
Thirty patients were evaluated. The sensitivity in our own population was 92%, specificity 
was 100%. Twenty-one articles were selected for our meta-analysis. Overall sensitivity 
and specificity was 96% and 100% respectively. Sensitivity and specificity for tumours in 
the adrenal gland was 98% for both. For tumours located outside the adrenal gland 
sensitivity was 98%. Sensitivity for malignancies was 79%. 
Conclusion 
123I-MIBG scintigraphy has an excellent sensitivity and specificity in localising 
phaeochromocytomas except for malignant tumours. 123I-MIBG scintigraphy is superior in 
localising tumours outside the adrenal gland.  
  





Phaeochromocytomas are rare catecholamine-secreting neuroendocrine tumours arising 
from chromaffin tissue of the adrenal gland or extra-adrenal paraganglia.1 
Phaeochromocytoma arising from the extra-adrenal paraganglia are also named extra-
adrenal phaeochromocytomas. About 80-85% of the phaeochromocytomas arise from the 
adrenal gland, about 15-20% arise from extra-adrenal paraganglia, in the 
retroperitoneum, in the mediastinum, the pelvic region, and in the head and neck 
region.2,3 The suspicion of a phaeochromocytoma is based on clinical signs and 
symptoms and includes a medical history of hypertension, episodic “spells” (i.e. 
headache, palpitation, sweating, pallor) or a family history of syndromes known to be 
associated with phaeochromocytomas.4-7 Laboratory investigations consist of the 
demonstration of biochemical excess of catecholamine and/or metabolites in blood 
and/or urine and should be performed for biochemical confirmation prior to the 
localisation of the tumour. Localisation of the tumour is necessary for surgical removal. 
This can be achieved by computed tomography (CT), magnetic resonance imaging (MRI) 
or metaiodobenzylguanidine (MIBG) scintigraphy. CT or MRI is mandatory for accurate 
anatomical information, especially since the introduction of laparoscopic techniques.8,9  
Sensitivity for tumour localisation varies between 87%-100% for CT and 91%-98% for 
MRI.10-14 Studies comparing CT and MRI are in favour for MRI.13-15 Sensitivity is about 
20% lower for phaeochromocytomas outside the adrenal gland, compared to 
phaeochromocytomas in the adrenal gland.14,16 The specificity of MRI is reported to be 
higher compared to the specificity for CT for tumours of the adrenal gland, between 88 
and 100% for MRI.4,14,17-19  
Wieland and colleagues developed the use of whole body MIBG scintigraphy in 1980.20 
MIBG is a guanithidine analogue that is structurally similar to norepinephrine and is taken 
up by adrenergic storage vesicles in the adrenal gland and the paraganglia, thus 
visualising neuroendocrine tissue. MIBG can be labelled with 131iodine(I) or 123I. The 
sensitivity of 131I-MIBG scintigraphy is limited and 123I-MIBG scintigraphy was introduced 
to improve the image quality and to increase sensitivity.21 However, 123I-MIBG is not 
widely available and more expensive. Recommendations on the use of MIBG scintigraphy 
in localising a phaeochromocytoma depend on the author. It is preferred as an initial 
diagnostic localising modality because whole body images can be obtained.14,22-26 It is 




gland and for confirmation of the lesion found on CT or MRI.15,27-32 Other authors do not 
recommend to routinely perform a MIGB scintigraphy.19,33-35 These diverse 
recommendations have several drawbacks. Most recommendations are based on studies 
using 131I as a label since this was introduced before the 123I-MIBG scintigraphy and 
because of better availability of 131I-MIBG in the USA. Furthermore, studies using  
123I-MIBG as a label are, because of the rarity of the disease, mostly retrospective and 
study population is relatively small.  
The aim of this study was to determine the diagnostic accuracy of 123I-MIBG scintigraphy 
in localising a phaeochromocytoma and to propose a diagnostic approach for localisation. 
We reviewed our 123I-MIBG scans and carried out a meta-analysis of previous studies, 
investigating the sensitivity and specificity of 123I-MIBG scintigraphy.   
 
 
Patients and methods 
 
Patients   
Between January 1992 and May 2002 all consecutive patients suspected of a 
phaeochromocytoma at the Department of Endocrinology were studied. Thirty-four 
patients were included. They had typical signs and symptoms combined with a consistent 
(>2 occasions) increase of urinary excretion of the fractionated metanephrines (i.e. 
normetanephrine and metanephrine). Patients whose 123I-MIBG scintigraphy was not 
available for reanalysis (n=1) and patients without a final diagnosis (n=3), were excluded. 
The charts of the remaining 30 patients were retrospectively reviewed for data about age, 
sex, the presence of a familial syndrome, lab investigations, radiology examinations and 
therapy. For the gold standard we used the pathology reports, if patients were operated. 
In those cases where histopathology was lacking, independent physicians were asked to 
review the case.  
 
Laboratory investigations 
The urinary excretion of fractionated normetanephrine and metanephrine was used for 
biochemical proof of increased catecholamine secretion. Fractionated total 
normetanephrine and metanephrine were determined using extractive derivatisation and 
stable isotope gas chromatography with mass fragmentographic detection.36 Values more 
than 1.5 times above the upper limit (normal value metanephrine: 33-99 µmol/mol 
                                                                                                       123I-MIBG scintigraphy in phaeochromocytoma 
 
97 




All MIBG scans were performed using 123I as a label. Injected dose was 185 MBq. Scans 
were acquired after 24 hours on dedicated gamma camera (DIACAM or MultiSPECT 2, 
Siemens, Hoffman Estates, IL, USA), in a 256 matrix, zoom factor 1.23, using a 15% 
window center around I-123 photopeak of 159 keV. The original 123I-MIBG scans were re-
evaluated by two experienced observers who were unaware of the clinical circumstances. 
Each independently rated the intensity the lesions, ranging from 0 to grade 3. A score of 
0 represented no uptake, grade 1 low uptake, lower than the liver, grade 2 moderate 
uptake equal to the liver and grade 3 intense uptake, more than the liver. Grade 2 and 3 
were defined as MIBG positive. A consensus was reached if there was a discrepancy 
between the two observers.  
 
Gold standard  
The histopathological diagnosis was considered the gold standard. A distinction was 
made between a phaeochromocytoma and hyperplasia. Hyperplasia was defined as 
glands harbouring tumour nodules less than 1 cm. Normalisation of the urinary excretion 
of the catecholamines metabolites was considered proof of absence of disease. Three 
independent physicians reviewed the medical charts of patients with persistent elevated 
urinary excretion of the catecholamine-metabolites in whom no histopathological 
diagnosis was obtained. They were unaware of the clinical outcome. Their consensus was 
considered the gold standard.  
 
Search strategy 
For the meta-analysis, we searched the literature. We selected studies, on the value of 
123I-MIBG scintigraphy, including studies with more than 5 scans. We used the clinical 
database MEDLINE (PubMed) using the following MESH headings and/or text words: 
MIBG, metaiodobenzylguanidine, MIBG scintigraphy, localisation, phaeochromocytoma, 
paraganglioma, sensitivity, and specificity. We also used the references of the identified 
papers. Only studies published in America or Europe were included. Studies were 
excluded if data from the same patients were used in more than one publication. We 





Using the mentioned golden standard for presence and absence of a 
phaeochromocytoma the MIBG scintigraphy was classified as true positive, true negative, 
false positive, and false negative on a patients level.  
For the meta-analysis, we used information of each 123I-MIBG scintigraphy given in the 
several studies. Because the number of studies overall, showed no heterogeneity 
regarding the effect estimates (sensitivity and specificity), we show the results of the 
pooled-analyses of sensitivity and specificity in the studies using fixed effects models 
using continuity correction. Fixed effects analysis computes the summary estimates of 
the sensitivity and specificity with its confidence interval of the individual studies, and 
Woolf's test for heterogeneity. The method that is presented in the table shows standard 
meta-analysis estimates and the 95% confidence interval with continuity correction for 
each study is given. Sensitivity has, by definition, been truncated at 1.0. Sensitivity of  
123I-MIBG scintigraphy for phaeochromocytoma inside the adrenal gland, outside the 
adrenal gland, and for malignant disease has been computed. Meta-analyses were 







Thirty patients were included. Median age was 44 years (range 23-78 years), 12 (40%) 
were men. Ten patients (33%) were evaluated because of a familial syndrome, 8 because 
of multiple endocrine neoplasia (MEN) type 2a, two because of Morbus Recklinghausen. 
Final diagnosis was phaeochromocytoma in 26 patients (87%). In 24 out of 26 patients, 
there was histopathological proof, in 2 patients the judgement of the reviewers served as 
the gold standard. Both patients had recurrent disease, 1 patient was not operated 
because of malignant disease, in the other patient imaging showed no tumour although 
he had a rise in the urinary excretion of normetanephrines 15 years after the resection of 
a phaeochromocytoma outside the adrenal gland. The tumour was located in the adrenal 
gland in 20 of 26 patients (77%), in 4 patients (15%) it was located outside the adrenal 
gland and 2 patients (8%) had malignant disease.  
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Four patients (13%) were classified with another diagnosis, 3 patients had a 
spontaneously normalisation of the urinary excretion of catecholamine-metabolites and 
remained free of symptoms after a median follow-up of 3 years. The remaining patient 
was analysed because of abdominal pain, spells and marginally raised urinary excretions 
of metanephrines. She was operated because of a suspected phaeochromocytoma 
outside the adrenal gland. During the operation no phaeochromocytoma could be 
detected and post-operatively the urinary excretion of metanephrines normalised 
spontaneously.  
 
Sensitivity and specificity of 123I-MIBG scintigraphy in our own population (Table 1) 
The 123I-MIBG scintigraphy was false negative in 2 patients. One 123I-MIBG scan did not 
localise a phaeochromocytoma in the right adrenal gland in a patient with MEN 2a 
syndrome and bilateral phaeochromocytoma. The tumour in the right adrenal gland had a 
diameter of 2.4 cm.  
 







Phaeochromocytoma (total) 24 2 26 
In adrenal gland 19 1 20 
MEN 2a 6 1 7 
        Unilateral 5 0 5 
        Bilateral 1 1 2 
Recklinghausen 2 0 2 
 
Sporadic 11 0 11 
Outside adrenal gland 3 1 4 
 
Malignant 2 0 2 
Other diagnosis, no phaeochromocytoma 0 4 4 
MEN denotes multiple endocrine neoplasia. 
 
Another false negative scan concerned the patient with the recurrent 
phaeochromocytoma 15 years after the resection of a phaeochromocytoma outside the 
adrenal gland. Thereby the sensitivity of the 123I-MIBG in the localisation of a 
phaeochromocytoma was 92%. There were no false positive results, thereby specificity 
was 100%. The patient operated on because of a suspected phaeochromocytoma, 




An additional single photon emission computed tomography (SPECT) view was available 
in 15 patients. It was of additional value in 2 patients, visualising a tumour in the adrenal 
gland that was not visualised with the planar view. 
 
Meta-analysis 
Using the mentioned search strategy we identified 20 articles studying the sensitivity 
and/or specificity of the 123I-MIBG scintigraphy. Twelve articles were included in meta-
analysis.12,19,24,28,34,35,37-42 Nine articles were excluded. Three articles from de Graaf and 
colleagues studied similar patients, the one that studied the most patients, was included 
in our meta-analysis.11,33,38 Two studies did not provide information about the final 
diagnosis.21,43 Three studies could not be included because no distinction was made 
between 131I-MIBG and 123I-MIBG scan.10,44,45 One further study was excluded because 
phaeochromocytomas as well as non-functioning paragangliomas were included, leaving 
12 articles for meta-analysis. The results are shown in Table 2. The overall sensitivity and 
specificity was 96% and 100% respectively. For phaeochromocytomas in the adrenal 
gland sensitivity and specificity both were 98%. Sensitivity for tumours located outside 
the adrenal gland was 98% and sensitivity for malignant disease was 79%. 
 
Table 2. Pooled sensitivity and specificity of 123I-MIBG scintigraphy, including own patients 
  
No observations 
Sensitivity 12,19,24,28,34,35,37-42   96 (94-99) 303 
Specificity 12,19,24,28,37,40,41  100 (99-100) 207 
Sensitivity in adrenal gland 12,19,28,34,41,42  98 (95-100) 133 
Specificity in adrenal gland 24,35*  98 (95-100) 357* 
Sensitivity outside adrenal gland 12,19,24,28,42  98 (91-100) 22 
Sensitivity malignancy 35  79 (37-100) 16 





This is the first meta-analysis concerning the accuracy of 123I-MIBG scintigraphy, 
confirming that it is an excellent diagnostic tool in localising a phaeochromocytoma with 
an overall sensitivity and specificity of 96% and 100% respectively.   
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The accuracy of 123I-MIBG scintigraphy appears to be superior in the visualisation of 
phaeochromocytomas located outside the adrenal gland compared to the in the literature 
reported sensitivity of 131I-MIBG scintigraphy, CT and MRI. In our meta-analysis sensitivity 
was 98% for pheochromocytomas located outside the adrenal gland, compared to a 
sensitivity of 80% for CT and MRI and 64% for 131I-MIBG scintigraphy.14,16,19 Although 
other studies also have reported this high sensitivity for tumours outside the adrenal 
gland, they were based on very few patients. Our meta-analysis includes 22 observations. 
We were not informed about possible interfering medication in the separate studies, so 
the sensitivity of 123I-MIBG scintigraphy could even be higher. Therefore for patients 
suspected of phaeochromocytoma, and no tumour localisation on MRI and/or CT one 
must always perform an 123I-MIBG scintigraphy to rule out tumours outside the adrenal 
gland (Figure 1). A complementary MRI or CT after the localisation with 123I-MIBG 
scintigraphy is helpful for anatomical information.   
Our meta-analysis has a drawback, since we excluded some papers. We found a high 
specificity for phaeochromocytomas in the adrenal gland. This high specificity of 123I-
MIBG scintigraphy is probably overestimated in patients with MEN type 2a. We excluded 
the article of de Graaf and colleagues, in which they studied patients with MEN type 2a. 
The 123I-MIBG scintigraphy was false positive in 5 out of 6 adrenal glands, 4 of them 
being classified as hyperplastic glands.33 Although hyperplasia is probably a precursor of 
a phaeochromocytoma, there is no evidence that a hyperplastic gland should be operated 
on.46,47 In conclusion, for patients with MEN type 2a, because of the risk of visualising a 
contralateral normal or hyperplastic gland, 123I-MIBG scintigraphy should probably not be 
performed (Figure 1).21,33,35,43  
On the other hand, in patients, without MEN type 2a, we suggest to perform an 123I-MIBG 
scintigraphy for confirmation of the tumour detected by MRI or CT. This can exclude the 
possibility of an incidentaloma and the possibility that the phaeochromocytoma is located 
outside the adrenal gland. These incidentalomas were found in 1.5% of CT scans in a 
large survey.48   
Although in our population 123I-MIBG scintigraphy showed 1 malignant lesion not 
visualised with MRI, the diagnostic value of 123I-MIBG scintigraphy for malignant tumours 
is disappointing. The sensitivity of 79%, however is based on only 16 patients. Affinity 
towards 123I-MIBG appears to be low for malignant tumours because dedifferentiated 
tumours can lose their ability to accumulate MIBG. In these patients whole body MRI or 6-





















Figure 1. Diagnostic approach in localising a phaeochromocytoma 
 
We conclude that the diagnostic value of 123I-MIBG scintigraphy is excellent. It should 
always be performed when MRI or CT fails to localise a tumour, which is more likely to 
occur when the tumour is located outside the adrenal gland. When MRI or CT localises a 
tumour in the adrenal gland in patients with MEN type 2a, 123I-MIBG scintigraphy should 
not be performed. The role of 123I-MIBG scintigraphy in malignant disease is disappointing 
and remains unclear. In summary Figure 1 shows the proposal for imaging studies in 
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Neuroendocrine tumours (NET) are a group of rare tumours, arising from cells of the 
neuroendocrine system. To this group belong midgut carcinoid tumours originating from 
the enterochromaffin cells of the bowel and phaeochromocytomas arising from 
chromaffin cells in the medulla of the adrenal gland and paraganglia.  
The aim of this thesis is to evaluate the course and follow-up of patients with NETs 
focussing on the midgut carcinoid tumours and phaeochromocytomas.  
 
Chapter 1 is a general introduction outlining the content of this thesis.   
In chapter 2 we present an overview of the literature concerning symptoms in patients 
with the carcinoid syndrome. This syndrome consists of symptoms such as diarrhoea, 
flushing and carcinoid heart disease. Most of the symptoms are caused by the secretion 
of biogenic amines or polypeptides, with serotonin being the most important biogenic 
amine secreted by the tumour. The carcinoid syndrome usually develops at the moment 
when large amounts of these factors enter the systemic circulation such as in patients 
with liver metastases. Therapy generally aims at lowering the concentration of secreted 
factors, but more specific interventions e.g. specific receptor blockers, inhibiting the 
effect of the secreted factor may also be useful. Disseminated midgut carcinoid tumours 
can in addition lead to pellagra and psychiatric problems. Pellagra, and maybe also 
psychiatric symptoms, are due to a depletion of the essential amino-acid tryptophan, 
competitively consumed by the carcinoid tumour for serotonin synthesis. 
Follow-up of patients with disseminated midgut carcinoid tumours includes measuring 
the urinary excretion of 5-hydroxyindolacetic acid (5-HIAA), plasma chromogranin A (CgA) 
concentrations, nuclear scans like 111In-octreotide scintigraphy (SRS), computed 
tomography (CT) and for screening of carcinoid heart disease echocardiography. However 
the optimal timing of these investigations is not yet totally clear.  
In chapter 3.1 we studied prognostic factors for survival in patients with disseminated 
midgut carcinoid tumours. Previously identified unfavourable factors for survival are high 
age, high urinary 5-HIAA concentrations at first visit, high plasma CgA concentrations, the 
presence of liver or lymph node metastases, the presence of carcinoid heart disease, the 
tumour size, and the histological grade of differentiation. We analysed 76 patients 
referred to the University Medical Centre Groningen between 1992 and 2003, with a 
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median survival from diagnosis of 74 months (95% confidence interval (CI) 61-88 
months).  
Prognostic factors for poor survival at referral were high age, high gamma-
glutamyltransferase levels and high urinary 5-HIAA concentrations. In a multivariate 
survival analysis with the urinary 5-HIAA concentration as a time dependent variable, the 
urinary 5-HIAA concentration was an independent prognostic factor for worse survival. 
(Hazard Ratio (HR) 1.007 (95% CI 1.004-1.010, P=0.000). This implies that patients with 
persistent low urinary 5-HIAA concentration have favourable outcome. Given the 
numerous drugs that seem to become available for these tumours it is helpful, in addition 
to radiological tumour measurements, to have a non-invasive marker that indicates 
prognosis during follow-up. Thus the urinary 5-HIAA concentration can assist in identifying 
patients who will benefit from a more intense follow-up and more aggressive 
management. 
Chapter 3.2 is a response to an article of Møller and colleagues addressing the topic of 
progression of carcinoid heart disease.1 One conclusion of their study was that 
somatostatin analogues did not prevent progression of carcinoid heart disease. In a 
series of 73 patients with the carcinoid syndrome treated in our hospital between 1985 
and 2002, we showed that the median urinary 5-HIAA concentrations gradually increased 
during follow-up and that in our population urinary 5-HIAA concentrations were lower 
compared to the referral population of Møller and colleagues. There are several data 
suggesting that serotonin is involved in the development of carcinoid heart disease, and 
somatostatin analogues inhibit the release of serotonin. Therefore the potential 
beneficial effects of somatostatin analogues on the prevention of carcinoid heart disease 
are not precluded in less advanced carcinoid tumours as seen in our hospital. 
In chapter 4 the effects of the functional polymorphisms of the serotonin transporter (5-
HTT) and Monoamine Oxidase-A (MAO-A) gene in patients with disseminated midgut 
tumours are described. Both genes are involved in the metabolism of serotonin. We 
hypothesized that, given the role of serotonin, the functional polymorphisms of the 5-HTT 
and the MAO-A could affect the symptoms of the carcinoid syndrome and survival. One 
hundred and five patients were genotyped for the promoter region of the 5-HTT gene (5-
HTTLPR) and the polymorphic region of the MAO-A gene (upstream variable number of 
tandem repeats (uVNTR-MAO-A)). For this study we reclassified the triallelic 5-HTTLPR in 
a biallelic model, according to previous studies; into a short (S’, functional less active 




Patients with the S’S’ genotype (n=29) of the 5-HTTLPR had a shorter overall survival, 
median 69.6 months (95% CI 20.8-118.3 months) compared to the patients with L’L’ 
(n=26) and L’S’ genotypes (n=49) who had a median survival of respectively 91.2 months 
(95% CI 41.4-140.8 months) and 114.6 months (95% CI 41.4-140.8 months) (P=0.001). 
No association was observed between the different genotypes of the 5-HTTLPR or uVNTR-
MOA-A and symptoms of flushes or diarrhoea at the moment of referral. Seven out of 26 
patients (26.9%) with the L’L’ genotype developed carcinoid heart disease compared to 4 
of the 49 patients (13.8%) with the L’S’ and 4 out of 26 patients (8.2%) with the S’S’ 
genotype (P=0.09). 
In the multiple logistic regression analysis the S’S’ genotype of the 5-HTTLPR, high age 
and high urinary 5-HIAA concentrations were independent predictors of dying within 7, 8, 
9 and 10 years after referral. Patients with the S’S’ genotype had an increased risk to die 
within 10 years after referral compared to patients with the L’S’ genotype with an odds 
ratio (OR) of 4.36 (95% CI 1.33-14.30, P=0.02). The shorter survival in patients with the 
S’S’ variant can be explained by the fact that these patients are probably exposed to high 
levels free serotonin for a longer period of time. Free serotonin is known for its several 
acute and chronic, especially cardiovascular harmful effects, like carcinoid heart disease. 
Genotyping patients with midgut carcinoid tumours for 5-HTTLPR can help identify 
patients who should be followed intensely with a more aggressive therapeutic approach.  
In chapter 5 we show the results of a feasibility study. Nine patients with advanced NETs 
were treated with interferon (IFN)-alpha-2b (2.5 million U/day subcutaneously), and after 
2 weeks, intravenous 5-fluorouracil (5-FU) 750 mg/m2 (day 2) and oral leucovorin 180 
mg/day (day 1 and 2) was added as a 2-weekly cycle. This combination was administered 
because of promising results obtained by others.3 The combination resulted in numerous 
side effects and only 3 patients completed more than 4 cycles. Interestingly serum levels 
of the angiogenic vascular endothelial growth factor (VEGF) decreased after treatment in 
7 out of 8 evaluable patients with a median of 40% namely  from a median level of 352 
pg/ml to 219 pg/ml. Less toxic combinations should be explored, also in combination 
with new antiangiogenic drugs, like bevacizumab which already showed antitumour 
activity in NETs. 
In chapter 6 a study is described which analyses the occurrence of sexual dysfunction in 
patients with disseminated midgut carcinoid tumours. These patients may be at risk of 
developing sexual dysfunction as serotonin plays in the brain a role in normal sexual 
behaviour. Data suggest that patients with midgut carcinoid tumours have serotonergic 
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dysfunctions in the brain. This is considered to be due to low tryptophan concentration in 
the brain as a consequence of tryptophan consumption by the tumour and the fact that 
serotonin does not cross the blood brain barrier. Furthermore serotonin has vasoactive 
properties that may lead to erectile problems and patients can suffer from pain, fatigue 
and use medication that can influence the sexual function. In this study 43 patients with 
disseminated midgut carcinoid tumours, 27 men and 16 women filled in a validated 
questionnaire for screening sexual dysfunction (QSD). The results were compared to a 
Dutch reference population. Dysfunction was defined as a sexual problem occurring at 
least regularly and experienced as at least stressful. Respectively 6 (22.2%), 4 (14.8%), 
and 7 (25.9%) of the male patients experienced sexual problems regarding arousal, 
orgasm and erection. One female patient (6.3%) experienced a problem regarding 
orgasm. Compared to the Dutch reference population, no differences were found.  
Male patients with a sexual dysfunction on any of the selected subscales had, compared 
to those without a sexual dysfunction, a longer duration of disease, namely 95.3 months 
(range 5.4-314.5 months) versus 18.6 months (range 0.6-167.9 months) (P=0.024), 
lower mean±SD plasma tryptophan concentrations of respectively 31.5±16.1 µmol/L and 
48.9±14.5 µmol/L (P=0.031) and more frequent IFN-alpha use, respectively 4 out of 8 
patients (50%) and 2 out of 19 (10.5%) (P=0.044). 
In conclusion patients with disseminated midgut carcinoid tumours do not experience 
sexual dysfunction more often compared to a population based reference population. 
However, physicians should be aware that sexual dysfunction in patients with midgut 
carcinoid tumours occurs especially in case of longstanding disease, with low plasma 
tryptophan concentrations and during IFN-alpha use.  
Finally, in chapter 7 we studied the diagnostic efficacy of 123iodine(I)-
Metaiodobenzylguanidine (MIBG) scintigraphy in patients with a phaeochromocytoma. We 
evaluated the 123I-MIBG scintigraphy of 30 patients and performed a meta-analysis 
selecting studies from the literature with more than five 123I-MIBG scans. The sensitivity in 
our population was 92%, specificity was 100%. Overall sensitivity and specificity in the 
meta-analysis was 96% and 100% respectively. Sensitivity and specificity for tumours in 
the adrenal gland was 98% for both. For tumours located outside the adrenal gland the 
sensitivity was 98%. Sensitivity for malignant phaeochromocytomas however was only 
79%. 123I-MIBG scintigraphy is superior over reported accuracy of computed tomography 
(CT) or magnetic resonance imaging (MRI) in localising tumours outside the adrenal 






During the last decades advances in the diagnostics and treatment of the relatively rare 
occurring NETs have been made. Patients with midgut carcinoid tumours often present 
with metastases. In this circumstance cure can hardly ever be achieved. Even when the 
disease is incurable, the prognosis is relatively good compared to other types of cancer, 
because of the often low-grade malignant characteristics of these tumours. Prognosis 
however, varies to a great extent between patients, and survival up to 20 years has been 
observed.  
Several prognostic factors have been identified, but in general (clinical) practice and in 
treatment guidelines these factors do not seem to influence treatment or the intensity of 
follow-up of patients with midgut carcinoid tumours. It is interesting to investigate the 
effect of using combinations of known combined prognostic factors, i.e. patients with the 
S’S’ genotype and urinary 5-HIAA concentration above 20 mmol/mol creatinine, on 
survival. Better knowledge could support improved evidence based follow-up frequencies 
for subgroups of patients. Given the rarity of midgut carcinoid tumours, an (inter)national 
database combined with a serum and tissue bank seems the way to answer these 
questions. This strategy could be favourable for other rare neuroendocrine tumours. 
Prognostic factors, like the urinary 5-HIAA concentration, might become important to 
identify patients who are eligible for, and who will benefit from, new treatment modalities. 
Currently several randomised studies are in progress to determine the effect of 
angiogenesis inhibitors and inhibitors of the mammalian target of rapamycin (mTOR).4-6 In 
these studies patients with radiological progressive disease are included, and regression 
of the identified lesions serves as outcome measure. To identify eligible patients frequent 
scans are required to prove progression. Since the urinary 5-HIAA concentration is a 
marker of impaired outcome, using the urinary 5-HIAA concentrations as an inclusion 
criterium, might make more patients eligible for inclusion 
New diagnostic modalities for patients with midgut carcinoid patients, like 6-[18F]-fluoro-L-
dihydroxyphenylalanine (18F-DOPA) positron emission tomography (PET), and [11C]-5-
hydroxytryptophan (5-HTP) PET with higher sensitivity compared to conventional imaging 
may play a role in treatment decisions.7,8 Although 18F-DOPA-PET is already used in 
patients with phaeochromocytomas, additional studies in both benign and malignant 
phaeochromocytomas will have to confirm its role.9 The same accounts for PET scanning 
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using various different tracers in other NETs, e.g. those NETs occurring in familial 
syndromes. For instance, if these new imaging techniques show more (extensive) lesions 
compared to convential imaging techniques, the prognostics value has to be considered 
before treatment decisions could be based on these findings. 
Imaging techniques will also have to focus on carcinoid heart disease. Until now the 
golden standard for diagnosing carcinoid heart disease is echocardiography. New cardiac 
imaging techniques like cardiac CT or cardiac MRI are more and more available and 
perhaps more sensitive in diagnosing carcinoid heart disease, although there are also 
developments in echocardiography.10,11  
Patients with midgut carcinoid tumours survive relatively long after diagnosis, interest in 
the quality of life of the patients is essential. The quality of life in general refers to the 
patient's ability to enjoy activities in daily life. Many aspects can influence this quality, i.e. 
specific symptoms, concerns about the future, and factors like sexual function. New 
developments in anti-cancer treatment but also guidelines for follow-up of patients will 
have to take into account its effects on the quality of life. 
Plasma testosterone concentrations are low in a subgroup of male patients with midgut 
carcinoid tumours. Supplementation with testosterone might be beneficial in male 
patients complaining of decreased libido and erectile dysfunction, and perhaps also 
beneficial for overall well being. However, until now this is not investigated and the 
underlying mechanism for low testosterone concentrations is not yet elucidated.  
Finally, giving the increasing options for diagnosis and treatment of patients with NETs 
optimal approach will more and more require a multidisciplinary task. There are many 
specialists involved like medical oncologists, endocrinologists, nuclear medicine 
specialists, surgeons, pathologists, gastroenterologists, cardiologists, clinical chemists, 
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Neuro-endocriene tumoren zijn zeldzame tumoren, die zowel goedaardig als kwaadaardig 
kunnen zijn. De tumoren zijn opgebouwd uit neuro-endocriene cellen. Gewoonlijk kunnen 
deze cellen hormoon producerende klieren vormen (bijvoorbeeld bijschildklieren, 
bijnieren). Daarnaast komen (neuro)endocriene cellen verspreid in verschillende organen 
voor: het diffuse neuro-endocriene systeem. De cellen zijn op verschillende plaatsen in 
het lichaam aanwezig en zijn in staat om allerlei stoffen produceren en uit te scheiden. 
Deze stoffen (zoals vasoactive aminen, polypeptiden en prostaglandines) hebben 
verschillende effecten op het lichaam. Bij patiënten met neuro-endocriene tumoren 
komen klachten voor die veroorzaakt worden wanneer de stoffen in grote hoeveelheden 
uitgescheiden worden. Dit geldt zowel voor goedaardige als kwaadaardige neuro-
endocriene tumoren. 
 
Het doel van dit proefschrift is om het beloop en de follow-up van patiënten met neuro-
endocriene tumoren te beschrijven. Hierbij hebben we ons gefocust op twee neuro-
endocriene tumoren.  
Ten eerste de carcinoïde tumoren van de middendarm. Dit zijn kwaadaardige tumoren 
die ontstaan uit neuro-endocriene cellen, die verspreid in de darm liggen en vaak in staat 
zijn om onder andere serotonine (vasoactive amine) te produceren. 
Ten tweede het feochromocytoom, een (meestal) goedaardige tumor die ontstaat uit 
neuro-endocriene cellen gelegen in het bijniermerg, die leidt tot een overmaat aan 
adrenaline en noradrenaline (vasoactive aminen).  
 
In hoofdstuk 2 wordt een overzicht gegeven van de verschillende symptomen die kunnen 
optreden bij patiënten met een carcinoïde tumor van de middendarm gegeven. Klachten 
kunnen ontstaan door de ligging en grootte van de tumor zelf, zoals darmobstructie, maar 
ook door overproductie van stoffen, voornamelijk serotonine. De combinatie van klachten 
die hierbij optreedt, wordt carcinoïdsyndroom genoemd. De drie belangrijkste symptomen 
van dit syndroom zijn diarree, flushes (opvliegers) en carcinoïde hartziekte. Diarree en 
flushes treden op in ongeveer 80% van de patiënten. De diarree wordt veroorzaak door 
serotonine en het feit dat bij de resectie van de primaire tumor een gedeelte van de darm 
wordt weggehaald. De oorzaak van de flushes is niet geheel duidelijke zowel serotonine 
als andere stoffen; tachykininen, catecholaminen en histamine worden hiervoor 
verantwoordelijk gehouden. Flushes kunnen worden uitgelokt door het eten van bepaald 
voedsel of drinken van bijvoorbeeld alcohol. Carcinoïde hartziekte wordt gekenmerkt door 
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schade aan de hartkleppen, vooral aan de rechterzijde van het hart (de tricuspidalis- en 
de pulmonalisklep). In deze kleppen treedt bindweefselvorming op (fibrosering), waarbij 
er zowel een vernauwing als een lekkage van die kleppen kan optreden. Dit kan 
uiteindelijk tot falen van de rechterhartkamer leiden. Patiënten met carcinoïde hartziekte 
hebben een slechtere overleving dan carcinoïd patiënten zonder hartziekte. Het 
vaststellen van carcinoïde hartziekte vindt plaats door middel van echocardiografie. In de 
toekomst zal onderzocht kunnen worden of nieuwere afbeeldingstechnieken zoals 
computertomografie (CT) of magnetic resonance imaging (MRI) een plaats hebben in het 
vaststellen van carcinoïde hartziekte. 
Het carcinoïdsyndroom treedt op als er al uitzaaiingen (metastasen) in de lever zijn. 
Serotonine, uitgescheiden door de tumor, wordt in de lever afgebroken tot 5-
hydroxyindolazijnzuur (5-HIAA). Wanneer grote hoeveelheden serotonine (en andere 
stoffen) in de bloedsomloop (circulatie) terechtkomen, en niet in de lever afgebroken 
worden, krijgt een patiënt klachten. De overproductie van serotonine door de tumor kan 
tevens leiden tot een tekort aan tryptofaan, het essentiële aminozuur dat een bouwsteen 
is voor de aanmaak van serotonine, maar ook belangrijk is voor gewone 
lichaamsprocessen. Zo is tryptofaan nodig voor de aanmaak van serotonine in de 
hersenen (serotonine passeert de bloedhersenbarrière niet) en voor de aanmaak van 
niacine (vitamine B3). Een niacine tekort leidt tot pellagra, een aandoening gekenmerkt 
door huidafwijkingen, dementie en diarree. Serotonine tekort in de hersenen (door een 
tryptofaan gebrek in de hersenen) kan leiden tot een verstoring van de slaap, de 
gemoedstoestand en het libido. 
Verschillende laboratorium bepalingen en beeldvormend onderzoek kunnen verricht 
worden om carcinoïde tumoren van de middendam te diagnosticeren en de 
uitgebreidheid vast te stellen. Dit kan zowel bij presentatie als gedurende de follow-up. 
De meest gebruikte laboratoriumbepalingen zijn de concentratie serotonine in 
trombocyten (voornamelijk bij het diagnosticeren) en de 5-HIAA concentratie in de urine 
en het chromogranine A  gedurende de follow-up. Beeldvormende technieken om de 
omvang en lokalisatie van uitzaaiingen vast te stellen zijn echografie, CT, MRI, 
somatostatinereceptorscintigrafie en tegenwoordig met positron emissie tomografie (PET) 
met verschillende metabole tracers. Verder is het van belang om regelmatig een 
echocardiogram te verrichten om carcinoïde hartziekte op te sporen. Het optimale 
moment en het interval waarin deze onderzoeken zouden moeten plaatsvinden is nog 




In geval van uitgezaaide ziekte is de behandeling meestal is gericht op het verminderen 
van klachten, het verbeteren van de kwaliteit van leven en het verbeteren van de 
levensverwachting. Somatostatine analogen verminderen de uitscheiding van de 
geproduceerde stoffen, zoals serotonine, waardoor klachten verminderen. Naast 
somatostatine analogen is interferon (IFN)-alfa geregistreerd voor de behandeling van 
deze tumoren. Van beide middelen is aangetoond dat in ongeveer 70% van de patiënten 
een vermindering optreedt van de klachten. 
 
De 5-jaarsoverleving van patiënten met een gemetastaseerde carcinoïde tumor van de 
middendarm is ongeveer 60%. De overleving verschilt aanzienlijk tussen patiënten. 
Ondanks het feit dat de tumor gemetastaseerd is, zijn er patiënten met een lange (> 20 
jaar) overleving. Het identificeren van patiënten met een slechte overleving na diagnose, 
maar ook gedurende de follow-up zou van invloed kunnen zijn op de frequentie van 
follow-up en op de beslissing van het starten van nieuwe behandelingen. In hoofdstuk 
3.1 worden prognostische factoren van overleving beschreven, zowel bij presentatie als 
gedurende de follow-up. 
Tussen 1992 en 2003 werden er op de afdeling Medische Oncologie in het Universitair 
Medisch Centrum Groningen (UMCG) 76 patiënten met een gemetastaseerde carcinoïde 
tumor van de middendarm behandeld. Gegevens, zoals leeftijd bij diagnose, de 
aanwezigheid van uitzaaiingen, 5-HIAA concentraties in de urine, leverenzymen (gamma 
GT en alkalisch fosfatase) bij initiële presentatie en gedurende follow-up werden 
geanalyseerd. De patiënten hadden een gemiddelde overleving van 74 maanden. Oudere 
patiënten, patiënten met en een hoog gamma GT en met een hoge 5-HIAA concentratie 
(> 20 mmol/mol kreatinine) in de urine hadden een slechtere overleving. Patiënten met 
een 5-HIAA concentratie > 20 mmol/mol kreatinine in de urine bij presentatie hadden 
een 5-jaarsoverleving van 26%, patiënten met een 5-HIAA concentratie ≤ 20 mmol/mol 
kreatinine in de urine bij presentatie een 5-jaaroverleving van 72%. Gedurende de follow-
up bleek de urine 5-HIAA concentratie een onafhankelijke (onafhankelijk van leeftijd en 
gamma GT) voorspeller voor overleving te zijn. Patiënten met een persisterende lage 
urine 5-HIAA concentratie hebben een betere overleving en deze marker kan dus in de 
praktijk gebruikt worden om patiënten met hoge excretie te identificeren die baat hebben 
bij een intensieve follow-up en mogelijk nieuwe middelen. 
Deze nieuwe middelen zijn voornamelijk gericht op het remmen van vaatnieuwvorming 
(angiogenese remmers). De behandeling van de patiënten is vaak gebaseerd op ziekte 
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activiteit gevonden op CT of MRI. Echter de progressie/ernst van ziekte bij patiënten met 
carcinoïde tumoren van de middendarm is niet altijd met beeldvorming vast te leggen. De 
5-HIAA concentratie in de urine zou eveneens als maat voor ziekteactiviteit gebruikt 
kunnen worden. Met deze marker zouden mogelijk meer patiënten kunnen deelnemen 
aan studies met nieuwe geneesmiddelen en daar de gunstige effecten van kunnen 
ondervinden. 
 
Hoofdstuk 3.2 is een reactie op een artikel van Møller (New England Journal of Medicine, 
2003). In dit artikel worden factoren beschreven die geassocieerd zijn met de progressie 
van carcinoïde hartziekte. Er zijn verschillende studies waaruit blijkt dat serotonine 
betrokken is bij de ontwikkeling van carcinoïde hartziekte. Somatostatine analogen 
verminderen de afgifte van serotonine door de tumor en kunnen theoretisch dus ook 
effectief zijn in de preventie van carcinoïde hartziekte. Echter een van de conclusies van 
Møller was dat somatostatine analogen geen invloed hadden op het voorkomen de 
progressie van carcinoïde hartziekte.  
In 73 patiënten met het carcinoïdsyndroom behandeld in het UMCG tussen 1985 en 
2002 toonden we aan dat de gemiddelde 5-HIAA concentratie in de urine steeg 
gedurende follow-up, maar dat in onze populatie deze 5-HIAA concentraties in de urine 
lager was vergeleken met de populatie van Møller. Dit betekent dat de conclusie van 
Møller niet te extrapoleren is naar patiënten met minder vergevorderde ziekte zoals in het 
UMCG. In deze patiëntengroep zouden somatostatine analogen nog steeds effectief 
kunnen zijn ter preventie van carcinoïde hartziekte. 
 
In hoofdstuk 4 wordt het effect beschreven van 2 functionele polymorfismen (een 
natuurlijk voorkomende variatie van een gen) in het serotonine transporter (SERT) gen en 
het Monoamine Oxidase-A (MAO-A) gen bij patiënten met een gemetastaseerde 
carcinoïde tumor van de middendarm. Zowel de SERT als het enzym MAO-A is betrokken 
bij de afbraak van serotonine tot 5-HIAA. Gezien de belangrijke rol van serotonine bij 
patiënten met een carcinoïde tumor van de middendarm, zou een functioneel 
polymorfisme in de genen betrokken bij de afbraak van serotonine, zowel het optreden 
van symptomen als ook de overleving kunnen beïnvloeden. Het polymorfisme in het SERT 
gen bestaat uit een korte variant (S: short) en een lange variant (L: long). Het L allel is 
functioneel actiever en leidt tot meer SERT transcriptie vergeleken met de S variant. Het 




polymorfisme een actievere (L) en een minder actievere (S) variant. In DNA van 107 
patiënten werden gekeken naar het polymorfisme van het SERT en het MAO-A gen.  
Patiënten met het SS genotype van het SERT gen (n=29) hadden een kortere mediane 
overleving, 69,6 maanden vergeleken met patiënten met het LL (n=26) en het LS 
genotype (n=49). Patiënten met het LL en LS genotype hadden een mediane overleving 
van respectievelijk 91,2 en 114,6 maanden (P=0,001). Patiënten met een SS genotype 
bleken een verhoogd risico op sterfte te hebben vanaf 7 jaar na verwijzing en 
gecorrigeerd voor de leeftijd en de 5-HIAA concentratie in de urine. Het risico op 
overlijden aan de ziekte binnen 10 jaar na verwijzing was 4,36 (odds ratio (OR): 4,36) 
maal zo groot vergeleken met patiënten met het LS genotype. Deze slechtere overleving 
bij patiënten met het SS genotype valt te verklaren doordat vrij serotonine langzamer 
wordt opgenomen en patiënten met het SS genotype daardoor langer bloot staan aan dit 
schadelijke vrije serotonine. Vrij serotonine is op korte en lange termijn schadelijk vooral 
voor hart en vaten. Het belangrijkste voorbeeld hiervan is het ontstaan van carcinoïde 
hartziekte. Er was geen associatie tussen deze verschillende genotypen en klachten van 
diarree en/of flushes. Er waren tevens geen verschillen in overleving tussen de 
verschillende genotypen van het MAO-A gen.  
 
Naast de prognostische factoren zoals beschreven in hoofdstuk 3a kan genotypering van 
patiënten helpen bij het identificeren van de groep patiënten die baat zouden kunnen 
hebben bij een intensievere follow-up en het eerder voorschrijven van nieuwe middelen. 
Bovendien ligt het combineren van de verschillende prognostische factoren (bijvoorbeeld, 
patiënten met het S’S’ genotype en een urine 5-HIAA excretie > 20 mmol/mol kreatinine) 
voor de hand. Gezien de zeldzaamheid van deze tumor leidt het vormen van combinaties 
natuurlijk tot kleine aantallen. Een (inter)nationale databank, gecombineerd met een 
serum en weefselbank is noodzakelijk om deze vraagstukken op te lossen. 
 
Hoofdstuk 5 beschrijft de resultaten van een studie naar de haalbaarheid van een 
behandeling met de combinatie IFN-alfa (2,5 miljoen E/dag subcutaan), gevolgd na 2 
weken met intraveneus 5-fluorouracil (5-FU) 750 mg/m2 (dag 2) en oraal leucovorin 180 
mg/dag (dag 1 en 2) in een 2 wekelijkse cyclus. Negen patiënten met gemetastaseerde 
neuro-endocriene tumoren werden hiermee behandeld. Deze combinatie ging gepaard 
met veel bijwerkingen en slechts 3 van de 9 patiënten voltooiden meer dan 4 cycli. 
Echter de serum concentratie van de vasculair endotheliale groei factor (VEGF) daalde 
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met ongeveer 40% tijdens de behandeling. Uit recente studies blijkt dat carcinoïde 
tumoren sterk gevasculariseerd zijn en dat VEGF en VEGF receptoren aanwezig zijn in 
deze tumoren. Momenteel wordt veel onderzoek verricht naar nieuwe angiogenese 
remmers, zoals bevacizumab. De onderzochte dosering van de combinatie IFN-alfa en 5-
FU gaat gepaard met te veel bijwerkingen echter gezien het anti-angiogenetische effect is 
het de moeite waard om minder toxische doseringen en combinaties te onderzoeken, 
eventueel in combinatie met de nieuwe angiogenese remmers. 
 
In de behandeling van patiënten met carcinoïde tumoren van de middendarm is kwaliteit 
van leven een belangrijk aspect, mede gezien de relatief lange overleving. In hoofdstuk 6 
wordt één aspect van deze kwaliteit belicht: het seksueel functioneren. Patiënten met 
een carcinoïde tumor van de middendarm zouden een vergrote kans kunnen hebben op 
het ontwikkelen van een seksuele disfunctie. De enige studie waarin dit onderzocht werd, 
dateert uit de jaren 70. Serotonine in de hersenen is betrokken bij het seksuele gedrag 
van mensen. Serotonine tekort in de hersenen zou invloed kunnen hebben op het 
seksuele gedrag van patiënten. Bovendien heeft serotonine vasoactieve eigenschappen 
die tot erectiele disfunctie bij mannen zouden kunnen leiden. Ook kan de fysieke conditie 
(pijn, moeheid) en het gebruik van geneesmiddelen het normaal seksueel functioneren 
beïnvloeden. In deze studie werden 43 patiënten, 27 mannen en 16 vrouwen, met een 
gemetastaseerde carcinoïde tumor gevraagd om de verkorte vragenlijst voor seksueel 
disfunctioneren (VSD) in te vullen. De uitkomst hiervan werd vergeleken met de uitkomst 
van een referentie populatie die diezelfde vragenlijst ingevulde. De referentie populatie 
bestond uit een steekproef uit de Nederlandse bevolking en werd uitgevoerd door de 
Rutger Nisso Stichting in verband met het beschrijven van seksueel gedrag bij de 
Nederlandse bevolking. Seksueel disfunctioneren werd door ons gedefinieerd als een 
seksueel probleem op de door ons geselecteerde subschalen (opwinding, erectie, 
orgasme, dyspareunie, ejaculatie en pijn), regelmatig voorkomend en stressvol. Van de 
27 mannen hadden er 6 (22,2%), 4 (14,8%), en 7 (25,9%) een seksuele disfunctie 
betreffende de opwinding, het orgasme en de erectie. Slechts één van de 16 vrouwen 
had een seksuele disfunctie betreffende het orgasme. Vergeleken met de referentie 
populatie werden geen verschillen aangetoond. 
Mannen met een seksuele disfunctie hadden vergeleken met mannen zonder een 
seksuele disfunctie een langere ziekteduur (95,3 maanden versus 18,6 maanden; 




µmol/L en 48,9 µmol/L (P=0,031) en zij gebruikten vaker IFN-alfa, te weten 4 van de 8 
patiënten (50%) en 2 van de 19 patiënten (10,5%) (P=0,004). Het plasma testosteron, 
LH en FSH verschilden niet tussen beide groepen. Wel bleken 7 (25,9%) van de 27 
mannen een verlaagde testosteronconcentratie te hebben. 
Concluderend komt seksueel disfunctioneren niet vaker voor bij patiënten met een 
carcinoïde tumor van de middendarm vergeleken met de Nederlandse bevolking. Echter 
artsen moeten zich wel bewust zijn dat seksueel disfunctioneren, kan optreden bij 
patiënten vooral bij mannen met al langer bestaande ziekte, met lage tryptofaan 
concentratie en bij gebruik van IFN-alfa.  
Testosteron suppletie zou kunnen helpen bij mannen met een verminderde libido of 
erectiele disfunctie en misschien ook wel bijdragen aan een verbetering van het 
welbevinden, hoewel nog niet duidelijk is wat het onderliggende mechanisme is van het 
verlaagde testosteron gehalte.  
 
In hoofdstuk 7 wordt de waarde van de 123I-meta-iodobenzylguanidine (MIBG) scintigrafie 
beschreven bij patiënten met een feochromocytoom. Een feochromocytoom ontstaat uit 
chromaffiene cellen en is bij de meeste patiënten gelegen in de bijnier. Bij ongeveer 10% 
van de patiënten is het feochromocytoom buiten de bijnier in een paraganglion gelegen, 
er wordt dan gesproken van een paraganglioom. Feochromocytomen zijn meestal 
goedaardig, bij ongeveer 10% van de patiënten is er echter sprake van een maligne 
feochromocytoom. Voor de diagnose feochromocytoom is het van belang om eerst 
biochemisch de afwijking vast te stellen. Dit gebeurt door het aantonen van een 
overmaat aan adrenaline en noradrenaline en de metabolieten hiervan in urine en 
tegenwoordig ook in plasma. Vervolgens dient beeldvormend onderzoek plaats te vinden. 
Voor een anatomische lokalisatie wordt een CT of MRI verricht. Ook nucleaire imaging is 
essentieel voor de lokalisatie van de tumor. MIBG is een analoog van noradrenaline en 
wordt opgenomen in de neuro-endocriene cellen van het feochromocytoom. Door MIBG te 
labelen met jodium kan het afgebeeld worden. Deze 123I-MIBG scan heeft als voordeel 
dat het gehele lichaam kan worden afgebeeld. De sensitiviteit voor het opsporen van 
feochromocytoom zou mogelijk beter zijn vergeleken met een CT of MRI. Door de 
zeldzaamheid van patiënten met een feochromocytoom zijn studies die de sensitiviteit en 
specificiteit onderzoeken vaak klein. 
Wij evalueerden de waarde van 123I-MIBG scintigrafie bij 30 patiënten en verrichtten een 
gestructureerd overzicht (meta-analyse). De sensitiviteit in onze eigen populatie was 92%, 
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de specificiteit 100%. In de meta-analyse was de sensitiviteit en specificiteit 
respectievelijk 96% en 100%. De sensitiviteit en specificiteit voor feochromocytomen in 
de bijnier was 98%. Voor feochromocytomen buiten de bijnier gelegen (paragangliomen) 
was de sensitiviteit 98%. De sensitiviteit voor maligne feochromocytomen was slechts 
79%. Concluderend is de sensitiviteit en specificiteit van de 123I-MIBG scintigrafie beter 
dan de gerapporteerde sensitiviteit en specificiteit van CT en MRI. Voor patiënten met 
maligne feochromocytomen is de 123I-MIBG scintigrafie weinig sensitief. Positron 
emission tomography (PET) met verschillende tracers (zoals 6-[18F]-fluoro-L-
dihydroxyphenylalanine (18F-DOPA), wordt op dit moment nog nader onderzocht bij zowel 
goed- als kwaadaardige feochromocytomen. Dit geldt tevens voor andere neuro-
endocriene tumoren. 18F-DOPA-PET is veel belovend en in een eerdere studie bij 
carcinoïde tumoren van de middendarm zeer sensitief.  
 
Tenslotte zullen, door de nieuwe diagnostische en behandelingsmogelijkheden, steeds 
meer disciplines betrokken zijn bij de zorg van patiënten met neuro-endocriene tumoren. 
Een multidisciplinair team van ervaren specialisten, te weten oncologen, endocrinologen, 
nucleair geneeskundigen, chirurgen, pathologen, gastro-enterologen, cardiologen, 
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List of abbreviations 
 
NET    neuroendocrine tumour 
WHO    World Health Organisation 
5-HTP    5-hydroxytryptophan 
TPH    tryptophan hydroxylase 
AADC    aromatic-L-amino acid decarboxylase 
IDO    indolamine dioxygenase 
TDO    tryptophan dioxygenase 
CgA    chromogranin A 
5-HIAA   5-hydroxyindolacetic acid 
CT    computed tomography 
MRI    magnetic resonance imaging 
SRS   somatostatin receptor scintigraphy 
MIBG    metaiodobenzylguanidine 
18F-DOPA   6-[18F]-fluoro-L-dihydroxyphenylalanine 
PET    positron emission tomography 
IFN    interferon 
MEN    multiple endocrine neoplasia 
SDH    succinate dehydrogenase 
NKA    neurokinin A 
SERT    serotonin transporter 
5-HTT    serotonin transporter 
MAO-A   monoamine oxidase-A 
5-HTTPLR   serotonin transporter gene–linked polymorphic region 
S    short 
L    long  
uVNTR   upstream variable number of tandem repeats 
VEGF    vascular endothelial growth factor 
5-FU    5-fluorouracil 
QoL    quality of life 
CHD    carcinoid heart disease 
TGF    transforming growth factor 
HR    hazard ratio 
List of abbrevations 
 
126 
CI    confidence interval 
mTOR    mammalian target of rapamycin  
GEP-NET   gastroenteropancreatic neuroendocrine tumour, 
NPK   neuropeptide K 
GI    gastrointestinal 
HPLC    high performance liquid chromatography 
ALP    alkaline phosphatase 
GT    gamma-glutamyltransferase 
PCR    polymerase chain reaction 
OR    odd ratio 
QSD    questionnaire for screening of sexual dysfunction 
EORTC   European Organization of Research and Treatment of Cancer 
QLQ-C30   quality of life-Core 30 Questionnaire 
LH     luteinizing hormone 
FSH     follicle stimulating hormone 



















Een proefschrift is, op een enkele uitzondering na, het resultaat van samenwerken. Ook 
dit proefschrift kwam tot stand door het samenwerken van bijzonderde individuen die 
betrokken zijn bij de behandeling van patiënten met neuro-endocriene tumoren. Bovenal 
ben ik de patiënten die deelnamen aan meerdere onderzoeken zeer erkentelijk.  
 
Ten eerste wil ik mijn eerste promotor Prof. dr. E.G.E. de Vries bedanken. Beste Liesbeth, 
ik voel me bevoorrecht dat ik jou als promotor heb gehad. Je enthousiasme, je werklust, 
je stimulans om nieuwe stappen te ondernemen en om projecten af te ronden, heb ik 
zeer gewaardeerd. Ik heb altijd het idee gehad dat ook voor jou, mijn onderzoek het 
belangrijkste was. Als ik de dankwoorden van je andere promovendi lees, begrijp ik dat zij 
dat gevoel delen. Ik hoop dat door mijn langere verblijf in het UMCG onze samenwerking 
voort zal duren. 
 
Daarnaast bedank ik mijn tweede promotor Prof. dr. P.H.B. Willemse. Beste Pax, als vast 
lid van onze onderzoeksgroep werd je hoogleraar en verwierf daarmee de mogelijkheid 
om mijn promotor te zijn. Bedankt voor de verhelderende en nuchtere kijk op de studies. 
Menig keer leidde jouw pennenstreken in mijn manuscripten tot hogere leesbaarheid.  
 
Natuurlijk bedank ik mijn co-promotor, Dr. T.P. Links. Beste Thera, je was in alle opzichten 
nauw betrokken bij mijn promotie. Ik prijs me bijzonder gelukkig jou als collega te 
hebben.  
 
De ideeën en kennis van mijn Co-promotor, Dr. I.P. Kema zijn in dit proefschrift van grote 
waarde geweest. Beste Ido, ik waardeer het feit dat je zo laagdrempelig bent, als het gaat 
om overleg. Ik ben blij dat er binnen het grote UMCG zulke korte lijnen bestaan.  
 
Co-promotor, Dr. A.N.M. Wijmenga, maakt mijn promotiecommissie compleet. Beste 
Machteld, dat je vanuit de periferie al die tijd betrokken bent geweest, bewonder ik. Velen 
nemen zich voor altijd betrokken te zijn bij onderzoek, maar weinigen brengen dit 
voornemen in uitvoering. Het zou mij niet verbazen als je ooit in een academisch 




Hoewel een proefschrift vooral tot stand komt door de betrokken onderzoekers, wil ik ook 
Prof. dr. B.H.R. Wolffenbuttel bedanken. Beste Bruce, dank dat je plaats neemt in mijn 
leescommissie. Je hebt meerdere keren gezegd dat je uitkeek naar het proefschrift en je 
hebt mij de gelegenheid gegeven het op een goede manier af te ronden.  
 
Prof. dr. C.J.M. Lips en Prof. dr. F.A.J. Muskiet wil ik bedanken voor hun bereidheid mijn 
proefschrift kritisch door te lezen. 
 
Ook dank aan datamanager Gerry Sieling. Beste Gerry, je hebt veel werk voor mij verricht.  
 
Alle medeauteurs die betrokken zijn geweest bij het schrijven van de hoofdstukken in dit 
proefschrift wil ik bedanken. 
Allereerst Dr. W.J. Post en Dr. H.M. Boezen voor de goede begeleiding op statistiek 
gebied. Drs. Madeleine H.E. Bruins Slot en Drs. Ellen van Ieperen hebben beiden als 
student meegeholpen. Prof. Dr. P.J. Jager, Dr. D.A. Piers en dr. J.P. Schouten wil ik 
bedanken voor hun bijdrage aan de MIBG studie. Verder wil ik Prof. dr. W.C.M. Weijmar-
Schultz, Dr. W.J. Meijer en Dr. W.W. de Herder bedanken voor de participatie in het 
onderzoek naar seksuele disfunctie bij carcinoïd patiënten. Dr. D.A.J Dijck-Brouwer, maar 
ook Astrid Brugman, Magdalena Huberts, Erik Nijboer en Ahmed Egal bedankt voor het 
vele werk aan de genotyperingen.  
Drs. J.A. Vroege, de maker van de vragenlijst voor seksueel disfunctioneren, wil ik 
hartelijk bedanken voor het geduldig beantwoorden van al mijn vragen.  
 
Dr. P.J. Perik, Dr. C. Buijs en Dr. C.H. Mom, beste Patrick, Ciska en Stijn, ik denk met heel 
veel genoegen terug aan de tijd samen, op het moment dat dit proefschrift gedrukt wordt, 
zijn jullie me al succesvol voor gegaan, nog eentje dus.  
 
Secretaresses van de Medische Oncologie, Gretha Beuker, Bianca Smit-Aeilkema, 
bedankt voor alle ondersteuning, ook toen ik niet meer bij de Oncologie werkte. 
 
Natuurlijk wil ik ook Saskia de Wildt en Margo de Boer-Themmen bedanken voor het feit 
dat zij mijn paranimfen willen zijn. Lieve Saskia, bijna 6 jaar geleden stond je ook naast 
me. De vriendschap van jou en Ron is me veel waard. 
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Lieve Margo, samen met Jaap neem je een belangrijke plek in ons leven in. Bedankt dat 
je ook deze dag naast me wilt staan. 
 
Tenslotte wil ik die mensen bedanken die niet direct bij mijn onderzoek betrokken zijn 
geweest maar het wel mogelijk hebben gemaakt om dit te bereiken.  
 
Lieve pap en mam, jullie hebben mij altijd gestimuleerd bij elke keuze die ik maakte. 
Verder hebben jullie me geleerd om altijd het beste uit mezelf te halen en alle 
mogelijkheden gegeven om zo ver te komen.  
Lieve papa en mama, de combinatie van gezin, werk en promoveren is door jullie hulp en 
steun mogelijk. 
Lieve Kasper en Bente, jullie maken van elke dag weer een feest.  
Tenslotte Iwan, me verdiepen in medisch onderzoek is de beste beslissing die ik ooit 
genomen heb, want daar ben ik jou tegengekomen. Het is de hoogste tijd dat we weer 
medeauteurs worden. 
